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COMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER 
PRODUCTS AND THE ENVIRONMENT 
 




The Committee on Carcinogenicity of Chemicals in Food, Consumer Products and 
the Environment (COC), is a UK committee of independent experts which advises 
the Department of Health, the Food Standards Agency and other government 
departments and agencies on the likelihood of cancer of chemicals found in food, 
consumer products and the environment. The COC has previously looked at whether 
drinking alcohol in alcoholic beverages causes cancer, and in 2013 it decided to look 
at the new evidence.  
Drinking alcohol has been shown to increase the risk (or chance) of getting 
some types of cancer. This does not mean that everyone who drinks alcohol will 
get cancer, but studies have shown that some cancers are more common in people 
who drink more alcohol. 
The World Health Organisation’s ‘International Agency for Research on Cancer’ 
(IARC) considers that drinking alcohol increases the risk of getting cancers of the 
mouth (oral cavity) and throat (pharynx), voice box (larynx), gullet (oesophagus), 
large bowel (colorectum) and liver, of breast cancer in women, and probably also of 
cancer of the pancreas. IARC made its most recent conclusions about alcohol and 
cancer after reviewing information that was available up to 2009. 
We have reviewed new information on alcohol and cancer that has become available 
since the 2009 IARC review. There are some limitations to the conclusions that we 
were able to make, because of the different ways research studies record data such 
as whether or not someone has a particular cancer and how much alcohol a person 
drinks. Overall, our findings support the view that drinking alcohol increases 
the risk of getting cancers of the mouth and throat, voice box, gullet, large 
bowel, liver, of breast cancer in women, and probably also of cancer of the 
pancreas. 
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The available information suggests that all types of alcoholic beverage can 
cause cancer, with little difference in risk from different drinks (e.g. beer, wine, 
spirits). The risk is due to the alcohol contained in the drink. The amount of alcohol in 
a drink varies: a single measure of spirit generally contains about 1 unit, whilst one 
medium-to-large glass of wine or one pint of beer typically contain around 2-3 units 
of alcohol. 
The new studies show that people who drink even low levels of alcohol have a 
greater risk of getting cancers of the mouth and throat, gullet, and of breast cancer in 
women than people who do not drink alcohol at all. Drinking approximately 1.5 units 
per day (10.5 units per week) or more increases the risk of cancers of the voice box 
and large bowel, whilst cancers of the liver and pancreas are more common in 
people who drink approximately 6 units per day (42 units per week) or more. The risk 
of getting these cancers increases the more alcohol a person drinks. 
There is very little specific information on binge drinking (drinking large 
amounts of alcohol on a single occasion) and cancer. Almost all of the new 
studies investigated the effect of total alcohol drunk over a period such as a week or 
a month on cancer risk, and not the amount of alcohol drunk on a single occasion. 
Scientists have identified a number of ways that alcohol can cause cancer. Both 
alcohol and its breakdown products can cause damage to cells, making them more 
likely to become cancerous. The speed at which alcohol is broken down and cleared 
from the body can differ between individuals due to genetic differences, and some of 
the new studies added to our knowledge about this. Alcohol may also interact with 
other cancer-causing chemicals (e.g. tobacco smoke in the mouth and throat), cause 
damage to liver cells leading to cirrhosis, alter levels of sex hormones (e.g. 
oestrogen, which may play a role in breast cancer), and alter vitamin and mineral 
levels (e.g. lower folate levels, which has been linked with risk of bowel cancer).  
We think that it is difficult to draw firm conclusions from a small number of studies 
that indicate that kidney cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, and 
extra-hepatic bile system cancer are less common in people who drink alcohol than 
in non-drinkers. However, it is clear that the increased risk of other cancers as a 
result of drinking alcohol far outweighs any possible decreased risk of these cancers. 
The effect of stopping drinking on cancer risk has been studied for some 
cancer types and risk decreases gradually after stopping alcohol 
consumption. However, it can take many years for the risk to fall to levels similar to 
those in people who have never drunk alcohol. Some studies show an increased risk 
initially, possibly due to people stopping drinking because of being unwell. Because 
the risk of cancer increases the more alcohol a person drinks, reducing consumption 
should reduce the risk of developing an alcohol-associated cancer, but we did not 
find any studies that had investigated this. 
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We looked at a number of publications estimating how many cancers occur in the UK 
each year as a result of people drinking alcohol. While there were some differences 
in how the analyses were carried out, using the two most appropriate studies 
produced useful estimates. We found that 4-6% of all new cancers in the UK in 
2013 were caused by alcohol consumption. 
Following our latest review we can say that: 
 Drinking alcohol causes cancers of the mouth (oral cavity) and throat 
(pharynx), voice box (larynx), gullet (oesophagus), large bowel (colorectum), 
liver and the female breast. Alcohol consumption probably also has a role in 
cancer of the pancreas. 
 People who drink even low levels of alcohol have a greater risk of getting 
some cancers than people who do not drink alcohol. 
Even at low levels of alcohol intake, below 1.5 units per day (10.5 
units per week), there is an increased risk of the following cancer 
types: 
- mouth and throat (oral cavity and pharynx) 
- gullet (oesophagus) 
- breast in women 
At alcohol intakes above approximately 1.5 units per day (10.5 units 
per week), there is an increased risk of the following cancer types:  
- voice box (larynx)  
- large bowel (colorectum) 
At high levels of alcohol intake, above approximately 6 units per day 




 The risk of getting cancer increases the more alcohol a person drinks. 
 The risk of getting some alcohol-related cancers gradually decreases over 
time in people who stop drinking alcohol, but it can take many years for the 
risk to fall to levels similar to those in people who have never drunk alcohol. It 
is logical to assume that reducing alcohol consumption would also lead to a 
reduction in cancer risk. 
v 
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ABV – alcohol by volume 
AC – adenocarcinoma 
ADH – alcohol dehydrogenase 
ALDH – aldehyde dehydrogenase 
ARCAGE – study on Alcohol-Related Cancers And Genetic susceptibility in Europe 
BMI – body mass index 
BRCA1, BRCA2 genes – genes linked with breast cancer  
CI – confidence interval 
CMO – Chief Medical Officer 
COC – Committee on Carcinogenicity of Chemicals in Food, Consumer Products 
and the Environment 
COM – Committee on Mutagenicity of Chemicals in Food, Consumer Products and 
the Environment 
CRUK – Cancer Research UK 
CYP2E1 – cytochrome P450 2E1 
DH – Department of Health 
DNA – deoxyribonucleic acid 
ER – oestrogen receptor 
g – grammes 
HBV – hepatitis B virus 
HCV – hepatitis C virus 
HL – Hodgkin lymphoma 
HPV – human papilloma virus  
IARC – International Agency for Research on Cancer  
vii 
INHANCE – International Head and Neck Cancer Consortium  
mL – millilitres 
MTHFR – methylenetetrahydrofolate reductase 
NHL – non-Hodgkin lymphoma 
OR – odds ratio 
ORcont  – odds ratio for a continuous variable 
p – probability value associated with a statistical test 
PHE – Public Health England 
ROS – reactive oxygen species 
RR – relative risk 
SCC – squamous cell carcinoma  
viii 
GLOSSARY OF TERMS 
Absolute risk: a measure of the association between exposure and outcome. 
Absolute risk difference (reduction) is the change in the risk from an exposure in 
relation to a comparison (reduced) exposure. 
Acetaldehyde: a metabolite of ethanol. 
Allele: one version of a gene at a given location (locus) along a chromosome. 
Attributable fraction: a measure of the impact of a causative factor on public health; 
the proportion of cases of a disease among exposed persons that can be attributed 
to the exposure. 
Binge drinking: high intake of alcohol on a single drinking occasion. 
Case-control study: a study that compares individuals who have a disease or 
outcome of interest (cases) with individuals who do not have the disease or outcome 
(controls), with regard to exposures experienced in the past. 
Causal association: when an exposure causes a particular outcome. 
Cohort study: a study design where a group of people (a cohort) is followed 
prospectively with respect to development of disease outcomes and exposures of 
concern (risk factors) and is then compared to a non-exposed group. 
Clastogenic: giving rise to or inducing chromosome breaks or other structural 
aberrations such as translocations. 
95% confidence interval (95% CI): a range within which we can be 95% sure that the 
true value of the entity we are estimating lies. 
Cytotoxic: toxic to cells. 
Confounder or confounding variable: an extraneous variable that satisfies BOTH of 
the conditions defined: (1) it is a risk factor for the disease under study (2) it is 
associated with the study exposure but is not a consequence of exposure. For 
example cigarette smoking is a confounding variable with respect to an association 
between alcohol consumption and heart disease. Failure to adjust for a confounding 
variable results in distortion of the apparent magnitude of the effect of the exposure 
under study. (In the example, smoking is a risk factor for heart disease and is 
associated with alcohol consumption but is not a consequence of alcohol 
consumption.) 
De novo: starting from the beginning; anew. 
Dose-dependent: when an outcome changes as a function of the exposed dose. 
Dose-response: a relationship in which a change in the amount, intensity, or duration 
of an exposure is associated with a change in risk of a specified outcome. 
ix 
Dose-response curve: a curve plotting the relationship between the size of a dose 
and the response to it. 
Epidemiological studies: studies designed to investigate associations, distribution, 
and control of disease (such as cancer) in human populations. 
Ever drinker: someone who has ever consumed alcohol. 
Exposure assessment methodology: how exposure (alcohol consumption) was 
measured, or estimated, in an epidemiology study, may include information on 
amount (number of drinks and the volume of the drinks), type of alcohol consumed, 
how often alcohol is consumed. 
Gene polymorphisms: natural variations in a gene, DNA sequence, or chromosome 
that have no adverse effects on the individual and occur with fairly high frequency in 
the general population. 
Genetic susceptibility (genetic predisposition): increased likelihood or chance of 
developing a particular disease due to the presence of one or more gene mutations 
and/or a family history that indicates an increased risk of the disease.  
Genotoxicity: the property of a chemical or agent that causes DNA damage. 
Genotype: 1] an individual's collection of genes, or 2] the two alleles inherited for a 
particular gene. 
Heterozygous: having two different forms of a gene that controls a particular 
characteristic, one inherited from each parent, and therefore able to pass on either 
form to any children. 
Incidence: a measure of the frequency with which an event, such as a new case of 
illness, occurs in a population over a period of time.  
Interaction (effect modification): interaction occurs when the direction or magnitude 
of an association between two variables differs due to the effect of a third variable. 
Inverse relationship: when an increase in exposure is associated with a decrease in 
a particular outcome, or vice versa. 
In vitro: a Latin term used to describe effects in biological material outside the living 
animal or plant (literally “in glass”). 
In vivo: a Latin term used to describe effects in living animals or plants (literally “in 
life”). 
J-shaped dose-response curve: a dose-response in which an apparent improvement 
in an endpoint occurs at low or intermediate levels of exposure to an otherwise toxic 
substance. 
Lifestyle factors: factors that can impact on health over which a person has control 
(e.g. smoking, alcohol, diet, exercise).  
x 
Meta-analysis: a method for systematically combining quantitative study data from 
several selected studies to develop a single conclusion that has greater statistical 
power. 
Multiplicative effect: an effect between two components that is greater than additive.  
Mutagenic/mutagenicity: the ability of a substance to cause a permanent change in 
the amount or structure of the genetic material in an organism or cell, which can 
result in a change in the observable physical, biochemical and physiological 
characteristics of a cell, tissue, organ or individual.  
Newcastle-Ottawa star scoring scheme: a tool used for assessing the quality of non-
randomised studies included in a systematic review and/or meta-analysis. 
Odds ratio (OR): a measure of association that compares the odds (chance) of 
getting a disease in those exposed to the odds of getting a disease in those not 
exposed. 
Pooled analysis: participant-level data from multiple studies are combined and 
analysed as a single dataset. 
Relative risk (RR): ratio of incidence of disease in exposed individuals to the 
incidence of disease in non-exposed individuals. 
Residual confounding: confounding that persists after attempts to adjust for the 
confounders measured in a study. 
Risk factor: any attribute, characteristic or exposure of an individual that increases 
the likelihood of developing a disease or injury.  
Statistically significant: Description of a result when the P-value associated with a 
statistical test of a comparison meets some pre-defined criterion e.g. P<0.05 or 5%.  
Upper aerodigestive tract: the mixed airway/gastrointestinal tract that includes the 
oral cavity, pharynx, paranasal sinuses, sinonasal tract, larynx, pyriform sinus, 
pharynx, and upper oesophagus. 
Variant allele (variant genotype): an alteration in the normal sequence of a gene 
(collection of genes), the significance of which is often unclear until further study of 
the genotype and corresponding phenotype occurs in a sufficiently large population. 
Complete gene sequencing often identifies numerous allelic variants (sometimes 
hundreds) for a given gene.   
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1 INTRODUCTION 
There are more than 200 types of cancer, each with different causes, symptoms and 
treatments. According to the cancer registry data, in the UK in 2013 approximately 
352,000 new cases of cancer were diagnosed and there were around 161,000 
deaths from cancer. Lifestyle choices such as alcohol1 consumption are known risk 
factors for certain types of cancer (CRUK, accessed 2015).  
This COC statement considers the most recently published literature on alcohol 
consumption and cancer risk. The causal association between alcohol and cancer, 
even where the overall increase in risk is small, has serious public health 
implications due to the large number of people who consume alcohol. In addition, 
consumption of alcoholic beverages may be one of the risk factors for cancer for 
which intervention can offer scope for reduction in cancer. 
1.1 Previous reviews of alcohol and cancer 
In 1995, we reviewed the carcinogenicity of alcoholic beverages across all cancer 
sites as part of the health input to the Interdepartmental Working Group on the 
Sensible Drinking Message (DH, 1995).  
We also considered the possible quantitative relationship between alcohol and 
oesophageal cancer, as part of the 1995 review of alcohol and cancer. Several 
studies indicated that there is a quantitative relationship between alcohol intake and 
squamous cell carcinoma (SCC) of the oesophagus, but a threshold level could not 
be defined. 
                                                          
 
1
 The term ‘alcohol’ is used throughout the text to refer to the ethanol contained in alcoholic 
beverages. 
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In 2005, we conducted a review of new data (post 1995) on the quantitative 
relationship between alcohol and SCC of the oesophagus. At this time, we 
considered that the new data strengthened the overall picture, with an increased risk 
apparent at intakes above 30 g ethanol (or approximately 4 units) per day (for a 
discussion of units of alcohol see section 1.2 below). However, it was not possible to 
identify a lower level of consumption below which there is no increase in risk (COC, 
2005). 
In 2004, we published a statement on alcohol and breast cancer and concluded that 
it is prudent to assume that drinking alcoholic beverages may cause breast cancer in 
women (COC, 2004). The research considered indicated that approximately 6% 
(between 3.2% and 8.8%) of breast cancers registered in the UK each year could be 
prevented if drinking was reduced to a very low level – i.e. less than 1 unit per week 
(8 g ethanol/week). The evidence suggested that the risk of breast cancer 
associated with drinking alcoholic beverages increases with prolonged consumption 
of alcohol. In terms of lifetime risk, a woman drinking 2 units per day (16 g 
ethanol/day) was estimated to have an 8% higher lifetime risk of breast cancer than 
a woman drinking 1 unit per day (8 g ethanol/day).  
The World Health Organisation's International Agency for Research on Cancer 
(IARC) reviewed the carcinogenicity of alcoholic beverages in 1987 (IARC, 1988), 
2007 (IARC, 2010) and 2009 (IARC, 2012). In their latest report, IARC (2012) 
concluded2 that:  
“There is sufficient evidence in humans for the carcinogenicity of alcohol 
consumption. Alcohol consumption causes cancers of the oral cavity, pharynx, 
larynx, oesophagus, colorectum, liver (hepatocellular carcinoma) and female 
breast. Also, an association has been observed between alcohol consumption 
and cancer of the pancreas. 
For cancer of the kidney and non-Hodgkin lymphoma, there is evidence 
suggesting a lack of carcinogenicity. 
There is sufficient evidence in humans for the carcinogenicity of acetaldehyde 
associated with the consumption of alcoholic beverages. Acetaldehyde 
associated with the consumption of alcoholic beverages causes cancers of 
the oesophagus and of the upper aerodigestive tract combined. 
There is sufficient evidence in experimental animals for the carcinogenicity of 
ethanol. 
There is sufficient evidence in experimental animals for the carcinogenicity of 
acetaldehyde. 
Alcohol consumption is carcinogenic to humans (Group 1). 
Ethanol in alcoholic beverages is carcinogenic to humans (Group 1). 
                                                          
 
2
 Definitions of evidence, as used in IARC Monographs for studies in humans are listed in Annex A. 
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Acetaldehyde associated with the consumption of alcoholic beverages is 
carcinogenic to humans (Group 1).” 
In the sections below we review epidemiology studies published since the IARC 
review in 2009, which investigated the association of the consumption of alcoholic 
beverages with these cancers. 
1.2 Consumption of alcoholic beverages in the UK 
The predominant types of commercially produced alcoholic beverages consumed in 
the UK are beer, wine and spirits. Some beverages are a combination of alcohol 
types such as fortified wine, in which spirits are added to wine. Alcopops were 
introduced to the drinks market in the mid-1990s and are a ready-mixed alcoholic 
drink of either wine or spirits with a soft drink such as lemonade. The strength of 
alcoholic beverages is commonly expressed as percentage alcohol by volume 
(ABV). Typically, beer contains 4-5% ABV, wine contains about 13% ABV and 
distilled spirits contain about 40% ABV (Drinkaware, 2015). However, lower or higher 
ethanol content in alcoholic beverages is also possible. Estimates of the 
consumption of alcoholic beverages in the UK are generally reported in terms of 
units of alcohol or grammes (g) of ethanol consumed per day. One UK unit of alcohol 
is defined as 10 millilitres (mL) or 8 g pure ethanol (the specific gravity of ethanol is 
0.8).The number of UK units of alcohol in a drink can be determined by multiplying 
the ABV by the volume of the drink (in mL) and dividing by 1000. This calculation 
allows a standardised comparison of the volume of pure alcohol between alcoholic 
beverages. Examples of the alcohol content of some typical alcoholic beverages are 
shown in Table 1.  
 
Table 1: Typical alcohol content in grammes and UK units of different alcoholic 
beverages 
 Typical ABV 
(%) 
Typical volume 
of a drink (mL) 
Ethanol 
content (g) 
UK units of 
alcohol 
Beer 4.5 568 (pint) 20 2.5 
Wine 13 175 (glass) 18 2.3 
Spirits 40 25 (single) 8 1.0 
1 UK unit = 8 g ethanol 
 
Worldwide, there is substantial variation in the reporting of alcohol intake levels and 
the terminologies used to describe levels of alcohol intake. Amounts of alcohol intake 
might be reported variously, for example, as grammes, millilitres, ounces, units or 
drinks consumed per day, week, month or year, as drink-years or g-years. In 
addition, the definition of a standard drink or unit of alcohol can vary substantially 
between different countries (IARD, 2015). For example, although in the UK, one unit 
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is considered to contain 8 g alcohol, one unit in the USA contains 14 g alcohol and in 
several European countries, one unit is 10 g alcohol. This can result in different 
levels used as benchmarks in epidemiological studies from different countries or 
continents. 
In the UK, alcohol consumption by adults has increased over the last 30 years, 
peaking in 2004 and with a subsequent downward trend (see CC/2013/13 for more 
detail). Evidence supports the view that men consume more alcohol than women, 
with the frequency of consumption increasing with age. Younger adults are more 
likely to drink heavily on a single occasion; however, this group also contains the 
fastest growing proportion of non-drinkers. Overall, there is substantial under-
reporting of alcohol consumption, as sales data exceed consumption calculations. 
Data from the Health Survey for England (as reported in the paper of Bellis et al., 
2015) indicate an average weekly alcohol consumption in 2012 by adults in England 
of 13.7 units (equivalent to approximately 2 units/day, or 16 g ethanol/day), 
accounting for around 63% of HMRC alcohol sales data. Bellis and colleagues 
estimated a typical weekly intake in adults in England of 17.1 units (equivalent to 
approximately 2.5 units/day, or 20 g ethanol/day) in the three-quarters of survey 
respondents who were current drinkers, taking into account ‘atypical’ (e.g. festivals, 
holiday periods) as well as ‘typical’ drinking periods. These data represented around 
79% of HMRC alcohol sales data (Bellis et al., 2015). 
1.3 Guidance on alcohol consumption in the UK 
Official guidance on alcohol consumption in the UK was first introduced in 1987. The 
current guidelines for lower risk drinking, which date from 1995, state that:  
“men should not regularly drink more than 3-4 units of alcohol per day and 
women should not regularly drink more than 2-3 units of alcohol per day. 
‘Regularly’ means drinking most days or every day”   (DH, 1995).  
The Government also offers guidance to women who are pregnant or trying to 
conceive, stating that: 
“women should avoid drinking alcohol. If they do choose to drink, the 
guidance, to protect the baby, is to drink no more than 1-2 units of alcohol 
once or twice a week, and not to get drunk” (NHS Choices, accessed 2015).  
In 2009, the Chief Medical Officer (CMO) of England also published guidance on 
alcohol consumption and young people (DH, 2009). 
In 2012, the House of Commons Science and Technology Committee recommended 
a review of the current lower risk guidelines. The Government response led to the 
initiation of a Department of Health (DH) and Public Health England (PHE) evidence-
based review of alcohol and alcohol guidelines (HM Government, 2012).  
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2 THE 2015 COC REVIEW OF ALCOHOL AND CANCER RISK 
We have reviewed epidemiology studies published since the most recent IARC 
review in 2009 (IARC, 2012), which evaluated the association of consumption of 
alcoholic beverages with the cancers listed by IARC as caused by drinking alcohol 
(see section 1.1). The new papers identified included cohort and case-control 
studies, and meta- and pooled analyses. While the cohort and case-control studies 
present new data, the meta- and pooled analyses include evidence from cohort and 
case-control studies published before 2009, as well as newer studies. 
2.1 Methodology 
We have considered review papers prepared by the PHE Toxicology Unit at Imperial 
College on the epidemiology studies published since the most recent IARC review in 
2009 on alcohol and the following cancer sites: upper aerodigestive tract (combined), 
oral cavity and pharynx, larynx, oesophagus, female breast, liver, colorectum, and 
pancreas. For details of the literature searches underpinning these papers, see 
Annex B. A quality scoring scheme was adopted for individual studies reviewed to 
provide an informal assessment of the studies and to help to identify key papers for 
potential future work on dose-response. This scoring scheme was similar to the 
Newcastle-Ottawa star scoring scheme and is attached as Annex C. The scoring 
scheme was used for the papers on cancers of the upper aerodigestive tract 
(combined), oral cavity and pharynx, larynx, oesophagus, female breast, liver, and 
colorectum.  
2.2 Findings 
Based on the data available across all the studies considered for each cancer site, 
we have identified broad categories of intake to help in our consideration of the 
findings. In describing levels of alcohol consumption, we will thus use the terms ‘low’, 
‘medium’ and ‘high’ to represent intakes averaging approximately <12.5 g 
ethanol/day (< approximately 1.5 units/day), 12.5-50 g ethanol/day (approximately 
1.5-6 units/day), and >50 g ethanol/day (> approximately 6 UK units/day), 
respectively.  
Due to the differences between countries, both in definition of a unit of alcohol 
(discussed in section 1.2) and in the volume of alcoholic drinks, there is much 
variation across all the available studies in the categories of alcohol intake used. 
Therefore, in selecting the cut-off values for these levels, we used the quantitative 
alcohol intake categories that broadly fit the available data and that were commonly 
used categories for some of the meta-analyses we considered. The ‘low’, ‘medium’ 
and ‘high’ descriptors we have given these categories are used as the most practical 
format for summarising overall findings from studies that we reviewed, but should be 
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considered in the context of current and any future UK alcohol consumption 
guidelines.  
The results listed in the following sections are presented as risk estimates. These 
vary depending on the study design, with odds ratios (OR) being commonly used for 
case-control studies and relative risks (RR) for cohort studies. However, they can all 
be interpreted as assessing by how much the risk associated with alcohol 
consumption increases or decreases. When statistical test results, including the tests 
of trend (p-trend), are quoted these are based on a 95% significance level. 
In drawing our conclusions for each cancer site, we have looked for consistencies in 
the evidence base as a whole and have accepted that there are uncertainties within 
studies and in extrapolating from studies. 
2.2.1 Alcohol and upper aerodigestive tract cancers 
Cancers of the upper aerodigestive tract (also often referred to as ‘head and neck’ 
cancers) comprise cancers of the oral cavity, pharynx, larynx and oesophagus. The 
majority of these cancers are squamous cell carcinomas (SCC) derived from the 
mucosal lining of these regions. These cancers are often combined into a single 
group for the purposes of epidemiological studies. 
Tobacco smoking is the most important risk factor for upper aerodigestive tract 
cancers and smoking cessation results in a decrease in risk. Consumption of 
alcoholic beverages also increases risk and a strong interaction between these two 
exposures has been noted. Other established risk factors for upper aerodigestive 
tract cancer sites include betel quid/areca nut chewing (mainly in India and Taiwan), 
occupational exposure to certain chemicals, poor oral health, and human papilloma 
virus (HPV) infection (CRUK, accessed 2015). 
2.2.1.1 Upper aerodigestive tract cancers (combined) 
In its evaluation of the carcinogenicity of alcohol in 2009, IARC stated that there is 
evidence that consumption of alcoholic beverages is causally related to cancers of 
the upper aerodigestive tract (combined), as it is for cancers of the oral cavity and 
pharynx, larynx, and oesophagus separately (IARC, 2012). We reviewed 
epidemiological reports on alcohol and cancers of the upper aerodigestive tract 
(combined) published since the last IARC review in 2009 (for details, see discussion 
paper CC/2015/05). Studies varied with respect to which cancer sites were included 
under the umbrella of ‘upper aerodigestive tract’ or ‘head and neck’ cancer, but 
generally did not include sites other than oral cavity, pharynx, larynx and/or 
oesophagus. A dose-dependent increase in risk with alcohol intake was noted in the 
majority of the analyses reported. Statistically significant increased risks were 
consistently seen at high levels of alcohol intake, and in some studies at medium-
level intakes.  
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A pooled analysis of case-control studies from the International Head and Neck 
Cancer Epidemiology Consortium (INHANCE) (Hashibe et al., 2009) indicated a 
statistically significant increased risk associated with ≥3 drinks/day (≥37.5 g 
ethanol/day) compared with never drinkers, and a strong and multiplicative combined 
effect of alcohol and tobacco smoking: 
Drinks/day g ethanol/day OR 95% CI 
1-2  12.5-<37.5  1.03 0.84-1.25 
≥3  ≥37.5   1.91 1.27-2.87 
≥3+smoking ≥37.5 + smoking  14.23 8.30-24.40 
  (>20 cigarettes / day) 
The Netherlands Cohort Study (Maasland et al., 2014) showed a statistically 
significant association of alcohol consumption with upper aerodigestive tract cancer 
incidence at intakes ≥15 g ethanol/day, with a strong dose-response (RR=1.20, 95% 
CI 1.12-1.27, per 10 g ethanol/day increment): 
g ethanol/day RR 95% CI 
>0-<5   1.11 0.75-1.65 
5-<15   1.15 0.77-1.71 
15-<30  1.52 1.02-2.27 
≥30   2.74 1.85-4.06 (p trend <0.001) 
The meta-analysis of Li et al. (2014) showed a statistically significant association of 
alcoholic beverage consumption with upper aerodigestive tract cancer mortality in 
people drinking >1 drink/day (>12.5 g ethanol/day) compared with non-/occasional 
drinkers: 
Drinks/day  g ethanol/day RR 95% CI 
≤1  ≤12.5   1.26 0.94-1.67 
2-3  12.6-49.9  1.79 1.26-2.53 
≥4  ≥50   3.63 2.63-5.00 
In summary: 
 The new publications add further weight to the existing view that consumption 
of alcoholic beverages is causally associated with risk of upper aerodigestive 
tract cancers (combined). Increasing alcohol consumption increased risk in a 
dose-dependent manner. 
 Statistically significant increased risks were generally observed at medium 
and high (>12.5 g ethanol/day), but not low alcohol intakes. 
2.2.1.2 Oral cancer (oral cavity and pharynx) 
Oral cancer as an overall term is often divided into the sub-categories of ‘oral cavity 
cancers’ and ‘pharyngeal cancers’. Cancers of the nasopharynx are not usually 
considered to come under the umbrella of oral cancer, although they are often 
reported in the literature with oral cancers. 
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In 2013, 8,580 new cases of oral cancer were diagnosed (5,713 in men and 2,867 in 
women) and there were 2,645 deaths from oral cancer (1,761 in men and 884 in 
women) in the UK.  
Tobacco smoking and drinking alcohol are established risk factors for oral cancer. 
Infection, most commonly with human papillomavirus (HPV), is also associated with 
increased risk (CRUK, accessed 2015). 
IARC has previously stated that alcohol causes oral cavity and pharyngeal cancer 
(IARC 1988, 2010, 2012). We reviewed epidemiological reports on alcohol and 
cancers of the oral cavity and pharynx published since the last IARC review in 2009 
(IARC, 2012) (for details, see discussion paper CC/2015/02). There was a general 
lack of uniformity among the studies evaluated in the definitions used to describe 
oral cavity and/or pharyngeal cancer. We also noted that many of the studies did not 
take into account the human papilloma virus (HPV) status of the participants. The 
evidence from these studies supported an association of alcoholic beverage 
consumption with oral cancer (oral cavity and pharynx combined) at all levels of 
intake. High-level alcohol intakes were also consistently associated with risk of 
cancers of the oral cavity or cancers of the pharynx when considered as separate 
sub-categories, however the findings were more variable at medium and low levels 
of alcohol drinking. 
Oral cavity and pharynx (combined): Meta-analyses reported by Tramacere et al. 
(2010) and Bagnardi et al. (2013; 2015) showed a statistically significant positive 
association between alcohol consumption and cancer of the oral cavity and pharynx 
(combined) at all levels of alcohol consumption, compared with non-/occasional 
drinkers: 
 Drinks/day  g ethanol/day RR 95% CI 
≤1  ≤12.5   1.21 1.10-1.33 
≥4  ≥50   5.24 4.36-6.30 (Tramacere et al. 2010) 
g ethanol/day RR 95% CI 
≤12.5   1.13 1.00-1.26 
≤50   1.83 1.62-2.07 
>50   5.13 4.31-6.10 (Bagnardi et al. 2015). 
Two Latin American case-control studies reported statistically significant positive 
associations for ever drinking and increasing cumulative exposure of alcohol and the 
risk of cancer of the oral cavity and oropharynx (combined) (Szymańska et al., 2011; 
Ferreira Antunes et al., 2013). 
Oral cavity: A statistically significant positive association between alcohol 
consumption and cancer of the oral cavity (as a whole) was reported in the majority 
of studies, regardless of study type. Risk was consistently elevated at high levels of 
alcohol consumption, while evidence for a positive association was less consistent at 
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lower alcohol drinking levels. Most of the pooled and meta-analyses reported 
statistically significant positive associations. The pooled analysis of Lubin et al. 
(2010) from the INHANCE consortium showed statistically significant association at 
low and high (but not medium) levels of alcohol intake compared with the referent of 
0.01-<1 drinks/day (0.1-<12.5 g ethanol/day): 
 Drinks/day g ethanol/day OR 95% CI 
 1-2.9  12.5-<37.5  1.26 1.0-1.6 
 3.0-4.9 37.5-<62.5  1.29 0.9-1.8 
5.0-10.0 62.5-125  1.87 1.2-3.9 (p trend <0.01) 
A subsequent breakdown by gender showed a statistically significant increased risk 
only at high alcohol intake in men (OR=1.75, 95% CI 1.1-2.8 for 5-10 drinks/day) 
(Lubin et al., 2011). A meta-analysis reported by Turati et al. (2010) showed 
statistically significant association of alcohol drinking with oral cavity cancer at both 
the low and high intake categories evaluated compared with non-/occasional 
drinkers, with a clear dose-response: 
Drinks/day g ethanol/day RR 95% CI 
≤1  ≤12.5   1.17 1.01-1.35 
≥4  ≥60   4.64 3.78-5.70 
Conversely, the pooled analysis of Hashibe et al. (2009) from the INHANCE 
consortium did not observe a statistically significant increased risk of cancer of the 
oral cavity at any level of alcohol intake compared with never drinkers: 
Drinks/day g ethanol/day OR 95% CI 
1-2  12.5-<37.5  0.88 0.65-1.20 
≥3  ≥37.5   1.05 0.62-1.77 
It is unclear whether missing data for alcohol frequency categories leading to 
reduced number of cases and controls may have contributed to this. With regard to 
sub-types within the oral cavity, the findings from a French case-control study (Radoï 
et al., 2013) and an international meta-analysis (Turati et al., 2010) suggest that the 
tongue, and possibly the floor of the mouth, may present specific target sites within 
the mouth.  
Pharynx: A statistically significant positive association between alcohol consumption 
and cancer of the pharynx was reported in the majority of studies. All of the pooled or 
meta-analyses reported a statistically significant positive association at high levels of 
alcohol intake, however, as with studies of oral cavity cancers, there was less 
consistent evidence of an association at lower levels of alcohol drinking. The pooled 
analysis of Hashibe et al. (2009) from the INHANCE consortium found a statistically 
significant increased risk of pharyngeal cancer from alcohol intakes of ≥3 drinks/day 
(≥37.5 g ethanol/day), compared with never drinkers: 
Drinks/day g ethanol/day OR 95% CI 
1-2  12.5-<37.5  1.26 0.92-1.73 
≥3  ≥37.5   2.94 1.73-5.02 
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The pooled analysis of Lubin et al. (2010) from the INHANCE consortium showed a 
statistically significant association at all intake levels compared with a referent 
category of 0.01-<1 drinks/day (0.1-<12.5 g ethanol/day): 
Drinks/day g ethanol/day OR 95% CI 
1-2.9  12.5-<37.5  1.2 1.0-2.9 
3.0-4.9 37.5-<62.5  2.30 1.7-3.1 
5.0-10.0 62.5-125  3.67 2.6-5.3 (p trend <0.01) 
A subsequent breakdown of these data showed statistically significant increased 
risks at all intake levels for oro-pharyngeal cancer and in the medium- and high-level 
intake categories for hypo-pharyngeal cancer (Lubin et al., 2011). The meta-analysis 
by Turati et al. (2010) showed statistically significant association of alcohol drinking 
with pharyngeal cancer at high but not low alcohol intakes compared with non- or 
occasional drinkers: 
Drinks/day g ethanol/day RR 95% CI 
≤1  ≤12.5   1.23 0.87-1.73 
≥4  ≥60   6.62 4.72-9.29 
In summary: 
 The new publications add further weight to the existing view that consumption 
of alcoholic beverages is causally associated with risk of cancers of the oral 
cavity and pharynx (combined). Increasing alcohol consumption increases risk 
in a dose-dependent manner. Statistically significant increased risks were 
observed at low, medium and high levels of alcohol intake. 
 The new publications add further weight to the view that consumption of 
alcoholic beverages is causally associated with the risk of cancer of the oral 
cavity. Statistically significant increased risks were consistently observed at 
high alcohol intakes (>50 g ethanol/day), but findings were more variable at 
medium and low intakes. 
 The new publications add further weight to the view that consumption of 
alcoholic beverages is causally associated with the risk of cancer of the 
pharynx. Statistically significant increased risks were consistently observed at 
high alcohol intakes (>50 g ethanol/day), but findings were more variable at 
medium and low intakes. 
2.2.1.3 Laryngeal cancer 
Cancer of the larynx accounted for 2,315 new cancer diagnoses (1,915 in men and 
400 in women) in 2013 in the UK and 843 deaths (667 in men and 176 in women) 
from laryngeal cancer occurred in the same period. 
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Major risk factors for laryngeal cancer are tobacco smoking and drinking alcohol – in 
particular, the combination of smoking and drinking regularly, which we discussed in 
our statement on mixtures (COC, 2010). Other potential risk factors include poor 
diet, human papilloma virus (HPV) infection, medical conditions such as HIV/AIDS, 
previous cancers, some occupational and/or environmental exposures, and family 
history of head and neck cancer (CRUK, accessed 2015). 
IARC has stated that alcohol causes cancer of the larynx (IARC, 2012). We reviewed 
epidemiological reports on alcohol and cancer of the larynx published since the last 
IARC review in 2009 (for details, see discussion paper CC/2015/03). The majority of 
the new publications described pooled and meta-analyses. An association of alcohol 
drinking with laryngeal cancer was noted in the majority of the analyses reported, 
with statistically significant increased risks seen consistently at high intakes and in 
some studies at medium-level intakes. 
The pooled analysis by Lubin et al. (2010) using data from the INHANCE consortium 
showed a statistically significant increased risk of laryngeal cancer at intakes of 5-10 
alcoholic drinks/day (62.5-125 g ethanol/day) compared with the referent category of 
0.01-<1 drinks/day (0.1<12.5 g ethanol/day), but not at lower levels: 
Drinks/day g ethanol/day OR 95% CI 
1-2.9  12.5-<37.5  1.05 0.8-1.4 
3.0-4.9 37.5-<62.5  1.08 0.7-1.6 
5.0-10.0 62.5-125  1.64 1.0-2.6 (p trend <0.01) 
A meta-analysis reported by Islami et al. (2010) indicated increased risk at alcohol 
intakes >1 drink/day (>12.5 g ethanol/day) compared with non-/occasional drinkers, 
but not at lower intakes: 
Drinks/day g ethanol/day RR 95% CI 
>0-1  >0-<12.5  0.88 0.71-1.08 
>1-<4  >12.5-<50  1.47 1.25-1.72 
≥4  ≥50   2.62 2.13-3.23 
The RRs estimated by the model for selected amounts of daily alcohol consumption 
were: 1.20 (95% CI 1.15-1.25), 1.45 (95% CI 1.33-1.57), 1.72 (95% CI 1.52-1.90), 
2.04 (95% CI 1.76-2.36), and 3.77 (95% CI 2.93-4.86) for 12.5, 25, 37.5, 50, and 100 
g ethanol/day, respectively (Islami et al., 2010). Meta-analyses by Bagnardi and 
colleagues (Bagnardi et al., 2013; 2015) also indicated increased risk of laryngeal 
cancer associated with alcohol intakes >12.5 g ethanol/day, but not at lower levels, 
compared with non-/occasional drinkers: 
g ethanol/day RR 95% CI 
≤12.5   0.87 0.68-1.11 
≤50   1.44 1.25-1.66 
>50   2.65 2.19-3.19. 
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In summary: 
 The new publications add further weight to the existing view that consumption 
of alcoholic beverages is causally associated with risk of laryngeal cancer. 
 
 Statistically significant increased risks were consistently observed at medium 
and high (>12.5 g ethanol/day) but not low alcohol intakes. 
2.2.1.4 Oesophageal cancer 
In 2013, 8,779 new diagnoses (5,848 in men and 2,931 in women) of oesophageal 
cancer were made in the UK, and 7,750 deaths occurred due to oesophageal cancer 
(5,275 in men and 2,475 in women).  
The majority (over 80%) of oesophageal cancers fall into one of two sub-types: 
squamous cell carcinoma (SCC) or adenocarcinoma (AC). Oesophageal SCC, which 
accounted for more than a quarter (28%) of oesophageal cancers diagnosed in 
England in 2008-2010, is found more commonly in the upper third and middle of the 
oesophagus, developing from the squamous cells that make up the inner lining of the 
oesophagus. Oesophageal AC, which accounted for just over one-half (55%) of all 
oesophageal cancers diagnosed in England in 2008-2010, derives from mucous-
producing glandular cells and occurs mostly in the lower third of the oesophagus. 
Tobacco use increases the risk of both SCC and AC oesophageal cancer. 
Oesophageal SCC has also been strongly linked with alcohol consumption. By 
comparison, research has indicated that oesophageal AC is linked with excess body 
weight and long-term acid reflux, which can lead to a pre-cancerous condition called 
Barrett’s oesophagus (CRUK, accessed 2015). 
IARC has stated that consumption of alcoholic beverages is causally related to 
squamous cell carcinoma (SCC) of the oesophagus, and that increasing alcohol 
consumption increases risk in a dose-dependent manner (IARC, 2012). IARC 
reported that there is a substantial body of evidence that alcoholic beverage 
consumption is not associated with adenocarcinoma (AC) of the oesophagus (IARC, 
2012). We evaluated epidemiological literature published since the 2009 IARC 
review (for details, see discussion paper CC/2015/04). Evaluations generally showed 
a positive association between drinking alcohol and oesophageal cancer, although 
one large-scale evaluation from the European ARCAGE study did not find a 
statistically significant association (Marron et al., 2012). Many studies evaluated risk 
by oesophageal cancer sub-type (AC or SCC), indicating a clear association of 
alcohol drinking at all intake levels with oesophageal SCC, supporting the IARC 
conclusion. For oesophageal AC, the new publications also supported the IARC view 
that drinking alcoholic beverages is not associated with oesophageal AC. 
Oesophageal SCC: Several pooled- or meta-analyses indicated a positive, causal 
association between drinking alcohol and oesophageal SCC, with association at all 
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levels of alcohol intake, and a clear dose-response observed. The pooled analysis of 
Rota et al. (2010), using mostly data from European populations, showed a strong, 
non-linear dose-response with RRs of 2.81 (95% CI 1.79-4.40) for 25 g ethanol/day, 
5.11 (95% CI 2.63-9.94) for 50 g ethanol/day, and 11.00 (95% CI 4.61-26.24) for 100 
g ethanol/day, respectively, compared with non-drinkers. The meta-analysis of 
Bagnardi et al. (2015) also indicated a statistically significant association at all levels 
of alcohol drinking compared with non-/occasional drinkers, and a clear dose-
response: 
g ethanol/day RR 95% CI 
≤12.5   1.26 1.06-1.50 
≤50   2.23 1.87-2.65 
>50   4.95 3.86-6.34 
Individual cohort and case-control studies evaluated also provided further evidence 
for a causal association between alcohol consumption and oesophageal SCC. 
Oesophageal AC: Studies indicated no positive association of alcohol consumption 
with oesophageal AC at any of the intake levels evaluated. A meta-analysis of 
studies worldwide showed a clear absence of association between alcohol drinking 
(‘drinkers’ versus ‘non-drinkers’) and risk of oesophageal AC (RR= 0.87, 95% CI 
0.74-1.01) and gastric cardia AC (RR=0.89, 95% CI 0.76-1.03) (Tramacere et al., 
2012a). A pooled analysis from the Barrett’s Esophagus and Esophageal 
Adenocarcinoma Consortium (BEACON) (mostly US-based studies) (Freedman et 
al., 2011) also showed no positive association of alcohol drinking and risk of 
oesophageal AC or oesophago-gastric junction AC at any alcohol intake level, 
compared with non-drinkers: 
    AC of:  Oesophagus  Oesophago-gastric 
junction 
 Drinks/day g ethanol/day OR 95% CI OR 95% CI 
 >0-<0.5 >0-<7.0  0.86 0.65-1.13 0.83  0.68-1.00 
 0.5-<1.0 7.0-<14.0  0.63 0.41-0.99  0.78  0.62-0.99 
1-<3  14-<42  0.81 0.60-1.09 0.77  0.62-0.94 
 3-<5  42-<70  0.86 0.59-1.24 0.93  0.73-1.19 
5-<7  70-<98  0.93 0.66-1.31 0.95  0.69-1.32 
 ≥7  ≥98   0.97 0.68-1.36 0.77  0.54-1.10 
      p trend 0.21  p trend 0.88 
The individual cohort and case-control studies published also indicated a lack of a 
causal association between alcohol consumption and oesophageal AC.  
In summary: 
 The new publications add further weight to the existing view that consumption 
of alcoholic beverages is causally associated with risk of squamous cell 
carcinoma (SCC) of the oesophagus. Increasing alcohol consumption 
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increases risk in a dose-dependent manner. Statistically significant increased 
risks were observed at low, medium and high alcohol intakes. 
 The new publications add further weight to the existing view that consumption 
of alcoholic beverages is not associated with adenocarcinoma (AC) of the 
oesophagus. 
2.2.2 Alcohol and female breast cancer 
Breast cancer accounted for 53,339 new diagnoses of cancer in women in the UK in 
2013. In the same year, 11,470 deaths occurred in women due to breast cancer. 
Breast cancer does also occur in men, however we are focussing on female breast 
cancer in our review because male breast cancer is much less common (333 new 
diagnoses3 and 96 deaths4) and no association with alcohol consumption has been 
established.  
Risk of breast cancer depends on many factors, including age, genetics (including 
BRCA1 and BRCA2 gene mutations) and exposure to risk factors. Female breast 
cancer is linked to various lifestyle factors including oestrogen exposure, being 
overweight and alcohol consumption. IARC and the World Cancer Research Fund 
cite the following factors for which there is convincing evidence of association with 
breast cancer: alcoholic beverages, diethylstilboestrol, oestrogen-progestogen 
contraceptives and menopausal therapy, X- and gamma radiation, body fatness, and 
adult attained height. They also note other risk factors for which there is evidence, 
including digoxin, oestrogen menopausal therapy, ethylene oxide, shift-work, 
tobacco smoking, height, weight and body-fat factors, and dietary fat intake. 
Breastfeeding and physical activity are associated with reduced risk of breast cancer 
(CRUK, accessed 2015). 
We previously evaluated research published to June 2003 on alcohol consumption 
and breast cancer, and concluded that drinking alcoholic beverages may result in 
breast cancer in women (COC, 2004). The research considered indicated that 
approximately 6% (3.2% to 8.8%) of breast cancers registered in the UK each year 
could be prevented if drinking alcohol was reduced to less than 1 unit/week (8 g 
ethanol/week). We noted that this implied that consuming 1 alcoholic drink per day 
(at the time equivalent to approximately 1 unit/day) has a measurable effect. IARC 
also concluded that alcohol consumption is causally associated with breast cancer 
(IARC, 2010; 2012). We reviewed new reports published since the 2009 IARC 
evaluation (for details, see discussion paper CC/2014/19). Compared to some of the 
other cancer sites we reviewed, there were many more new cohort and case-control 
                                                          
 
3
 2013 data for England and Scotland and yearly average data (2009-2013) for Northern Ireland. No data 
available for Wales 
4
 2013 data for England, Wales and Scotland and yearly average data (2009-2013) for Northern Ireland. 
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studies, as well as a number of new meta-analyses. Most of the meta-analyses 
observed a positive association (Brennan et al., 2010; Seitz et al., 2012; Trentham-
Dietz et al., 2014; Bagnardi et al., 2015), as did the majority of cohort and case-
control studies. 
The meta-analysis of Bagnardi et al. (2015) indicated a statistically significant 
increased risk at all alcohol consumption levels compared with non-/occasional 
drinkers, with a clear dose-response: 
g ethanol/day RR 95% CI 
≤12.5   1.04 1.01-1.07 
≤50   1.23 1.19-1.28 
>50   1.61 1.33-1.94 
 
The large meta-analysis of Seitz et al. (2012) indicated an RR of 1.04 (95% CI, 1.02-
1.07) associated with alcohol intake of ≤1 drink/day (≤12.5 g ethanol/day) compared 
with non-drinkers. Since the last IARC review, more studies have been published 
that evaluated the relationship between alcohol and type of breast cancer (ductal or 
lobular) or receptor status. Ductal and lobular carcinomas account for approximately 
90% and 10%, respectively, of invasive breast cancers in women in the UK. Most of 
the results showed similar effects for either sub-type (Kotsopoulos et al., 2010; Chen 
et al., 2011; Newcomb et al., 2013), but one showed a slightly stronger positive 
association for lobular tumours (Li et al., 2010) and another showed no association 
for ductal carcinoma in situ (Kabat et al., 2010). There is increasing evidence to 
indicate a stronger association between alcohol consumption and ER-positive than 
ER-negative tumours (Li et al., 2010; Kabat et al., 2010), however risks are 
increased for tumours with either receptor status. We note that there were some 
limitations in terms of disease ascertainment, exposure assessment methods and 
lack of adjustment for confounders in some of the studies. There were a number of 
new studies on breast cancer mortality and recurrence. Overall, there was 
inconsistency across these studies, and therefore we are uncertain of the effect of 
alcohol consumption on recurrence and mortality. 
In summary: 
 The new evidence is consistent with the existing view that alcohol 
consumption is causally associated with female breast cancer. Increasing 
alcohol consumption increases risk in a dose-dependent manner. 
 Overall, the new publications indicate a statistically significant increased risk 
at low, medium and high alcohol intakes.  
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2.2.3 Alcohol and liver cancer 
In 2013, there were 5,373 new diagnoses of liver cancer (3,466 in men and 1,907 in 
women) in the UK and 4,846 deaths due to liver cancer (2,934 in men and 1,912 in 
women).  
It has been estimated that 42% (49% in males and 28% in females) of liver cancer 
cases in the UK are associated with lifestyle factors, including tobacco smoking 
(23%), infections (16%), and alcohol consumption (9%). An estimated 90% of liver 
cancer cases in developing countries and 40% in developed countries are caused by 
hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Oral contraceptives, 
ionising radiation, some occupational exposures, being overweight and obesity have 
been cited as possible risk factors. Diseases with a genetic aetiology that can 
increase the risk of liver cancer include haemochromatosis and Wilson's disease 
(CRUK, accessed 2015). Dietary exposure to aflatoxins from crops such as corn and 
peanuts is a risk factor that is present mostly in developing countries (WCRF, 2015). 
IARC has stated that alcohol consumption is causally associated with liver cancer 
(IARC, 1988, 2010, 2012). We reviewed epidemiological literature published since 
the 2009 IARC review that reported evaluations of the association of alcohol intake 
with liver cancer (for details, see discussion paper CC/2014/12). A consistently 
positive association was observed between alcoholic beverage consumption and 
liver cancer at high intakes.  
The meta-analysis of Bagnardi et al. (2015) showed an association of alcohol 
consumption with increased risk of liver cancer at intakes >50 g ethanol/day, but not 
at lower levels, compared with non-/occasional drinkers: 
g ethanol/day RR 95% CI 
≤12.5   1.00 0.85-1.18 
≤50   1.08 0.97-1.20 
>50   2.07 1.66-2.58 
The meta-analysis of Turati et al. (2014) indicated a statistically significant increased 
risk at alcohol intake ≥37.5 g ethanol/day compared with non-drinkers: 
 Drinks/day g ethanol/day RR 95% CI 
 <3  <37.5   0.91 0.81-1.02 
 ≥3  ≥37.5   1.16 1.01-1.34 
Dose-response analysis from this study indicated a linear relationship between 
alcohol intake and liver cancer risk with RRs (95% CI) of 1.06 (1.02-1.11) for 12.5 g 
ethanol/day, 1.13 (1.04-1.24) for 25.0 g ethanol/day, 1.29 (1.08-1.53) for 50 g 
ethanol/day, 1.46 (1.13-1.89) for 75 g ethanol/day, and 1.66 (1.17-2.34) for 100 g 
ethanol/day. A statistically significant increased risk of liver cancer associated with 
high levels of alcohol drinking was also seen in the majority of individual cohort 
studies reviewed and in one nested case-control study.  
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In considering the new evidence on alcohol consumption and liver cancer risk, we 
noted that the majority of studies had been carried out in Asian populations. For liver 
cancer in particular, this gave rise to additional uncertainty in applicability of the 
findings to the UK population as a result of confounding by liver cancer arising from 
hepatitis. This was a particular concern as not all studies either established hepatitis 
status of the participants at the start or controlled for hepatitis in the analysis.  In 
addition, some of the studies were designed to investigate hepatitis rather than 
alcohol. It is not clear whether this would affect relative risk estimations, while it 
would be important in terms of absolute risk. Other factors were also noted, such as 
differences in the types of alcohol consumed in these studies compared to the UK 
and the deficiency in the alcohol dehydrogenase 2 (ADH2) enzyme in Asian 
populations, but these were an uncertainty across all the cancer sites. An apparent 
J-shaped dose-response curve was identified in some analyses, with increased risk 
seen in non-drinkers compared with low-level alcohol consumption. We consider that 
it is difficult to suggest a plausible mechanism for this, that there are shortcomings in 
the data, and that it would be difficult to investigate the size of the effect with the 
methods available. 
In summary: 
 The new evidence is consistent with the existing view that alcohol 
consumption is causally associated with liver cancer. A consistently positive, 
statistically significant association was observed at high intakes. 
2.2.4 Alcohol and colorectal cancer 
Colorectal (‘bowel’) cancer accounted for 41,075 new cancer diagnoses in 2013 in 
the UK (22,943 in men and 18,132 in women). In the same year, 15,954 deaths were 
caused by colorectal cancer (8,658 in men and 7,296 in women).  
CRUK note that the risk of colorectal cancer is related to age, genetics and exposure 
to specific risk factors. It has been estimated that slightly more than half of colorectal 
cancers in men and women in the UK are attributable to lifestyle factors, including 
consumption of red and processed meats, being overweight or obese, alcohol 
consumption, and smoking. Some medical conditions, such as inflammatory bowel 
diseases may also be associated with increased risk. Dietary fibre and physical 
activity are associated with reduced risk of colorectal cancer (CRUK, accessed 
2015). 
IARC has stated that there is sufficient evidence to conclude that consumption of 
alcoholic beverages is causally related to cancer of the colorectum (IARC, 2010; 
2012). We reviewed epidemiological evaluations on alcohol and colorectal cancer 
published since the 2009 IARC review (for details, see discussion paper 
CC/2014/20). Overall, the findings were variable, with the majority of individual new 
cohort and case-control studies showing no statistically significant positive 
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association between alcohol consumption and colorectal cancer, but pooled- and 
meta-analyses, which also include older studies, showing associations at high and in 
some cases medium intake levels.  
Pooled analyses from the US Nurses’ Health Study and Health Professionals Follow-
up Study (Cho et al., 2012; Nan et al., 2013) revealed RRs around 1.35 for 
individuals consuming ≥30 g ethanol/day compared with non-drinkers, whilst 
evaluation of lower intake categories in the study of Cho et al. did not show a 
statistically significant increased risk:  
g ethanol/day  RR 95% CI 
0.1-<5   1.16 0.87-1.54 
5.0-<10   1.08 0.91-1.28 
10-<15  1.26 0.96-1.66 
15-<30  1.11 0.92-1.33 
≥30   1.36 1.10-1.68 (p-trend 0.14)  
Further analysis by Cho and colleagues indicated that the increased risk at intakes 
≥30 g ethanol/day was statistically significant in subjects with (RR=2.02, 95% CI 
1.30-3.13) but not without (RR=1.23, 95% CI 0.96-1.57) a family history of colorectal 
cancer. Meta-analyses by Fedirko et al. (2011) and Bagnardi et al. (2013; 2015) 
showed increased risk of colorectal cancer, compared with non-drinkers, associated 
with alcohol intakes >12.5 g ethanol/day but not at levels below this: 
g ethanol/day RR 95% CI 
≤12.5   0.99 0.95-1.04 
≤50   1.17 1.11-1.24 
>50   1.44 1.25-1.65 (Bagnardi et al. 2015) 
Drinks/day  g ethanol/day RR 95% CI 
≤1  ≤12.5   1.0 0.95-1.05 
2-3  >12.5-<50  1.21 1.13-1.28 
≥4  ≥50   1.52 1.27-1.81 (Fedirko et al. 2011) 
An alternative analysis by Fedirko et al. (2011) showed RRs of 1.07 (95% CI 1.04-
1.10), 1.18 (95% CI 1.12-1.25), 1.38 (95% CI 1.28-1.50), and 1.82 (95% CI 1.41-
2.35) for 10, 25, 50, and 100 g ethanol/day, respectively. 
In summary: 
 Most of the evidence from the new meta-analyses is consistent with the 
existing view that alcohol consumption is causally associated with colorectal 
cancer. However, the majority of the new cohort and case-control studies 
published since 2009 showed no statistically significant positive association. 
 The positive associations were observed at medium and high (>12.5 or >30 g 
ethanol/day) but not low alcohol intakes. 
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2.2.5 Alcohol and pancreatic cancer 
Pancreatic cancer accounted for 9,389 new cancer diagnoses in the UK in 2013 
(4,706 in men and 4,683 in women) and caused 8,524 deaths (4,234 in men and 
4,290 in women).  
Tobacco is a major risk factor for pancreatic cancer and body fatness is cited by 
IARC as a risk factor. Probable risk factors are cited as alcohol, ionising radiation, 
excess abdominal fat, red meat and attained height. Some other factors that have 
been associated with pancreatic cancer risk include certain medical conditions (e.g. 
pancreatitis, diabetes), genetic conditions such as Peutz-Jeghers syndrome, and 
hepatitis B virus (HBV) and H. pylori infections (CRUK, accessed 2015). 
IARC (2012) concluded that there is accumulating evidence that high alcohol intake 
(≥30 g/day) is associated with a small increased risk of cancer of the pancreas, but 
could not exclude the possibility that residual confounding by smoking may partly 
explain this association. We reviewed epidemiological evaluations on alcohol and 
pancreatic cancer published since the 2009 IARC review (for details, see discussion 
paper CC/2014/02). Overall, the new publications supported the conclusion of IARC 
that low-to-medium levels of alcohol consumption are not associated with increased 
pancreatic cancer risk, but high levels may increase risk.  
A pooled analysis by Michaud et al. (2010) showed no statistically significant 
association of alcohol intakes at levels up to ≥60 g ethanol/day with pancreatic 
adenocarcinoma incidence, compared with the referent group (>0-<5 g ethanol/day): 
   g ethanol/day  OR 95% CI 
   0   1.19  0.97-1.48 
   >0-<5   1.00 (ref) 
   5-<10   1.00 0.78-1.28 
   10-<15  1.15  0.85-1.54 
   15-<30  1.08  0.83-1.40 
   30-<45  1.36  0.99-1.88 
   45-<60  0.86  0.54-1.37 
   ≥60   1.38  0.86-2.23 (p trend 0.11) 
    ORcont5 1.03  0.97-1.10 
 
The pooled analysis of Lucenteforte et al. (2012) showed some statistically 
significant associations at very high alcohol intakes compared with abstainers or 
occasional drinkers (<1 drink/day):  
                                                          
 
5
 per 15 g ethanol/day 
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Drinks/day  g ethanol/day  RR 95% CI 
0-1  0-<12   1  (ref) 
1-2  12 - <24  1.02 0.76-1.37 
2-3  23.6 - <36  0.91  0.73-1.15 
3-4  36 - <47  0.93  0.69-1.26 
4-5  47 - <59  1.26  0.99-1.61 
5-6  59 - <71  1.14  0.86-1.50 
6-7  71-<83  1.59  1.16-2.20 
7-8  83 - <95  1.30  0.81-2.09 
8-9  95 - <107  1.25  0.74-2.10 
≥9  ≥107   1.60  1.16-2.22 (p trend 0.302) 
The meta-analysis of Bagnardi et al. (2015) indicated a statistically significant 
increased risk of pancreatic cancer associated with alcoholic beverage intake at >50 
g ethanol/day compared with non- or occasional drinkers, but this was not observed 
at lower intake levels:  
g ethanol/day RR 95% CI 
≤12.5   0.95 0.89-1.01 
≤50   1.03 0.97-1.09 
>50   1.19 1.11-1.28 
The exact role of alcohol consumption in pancreatic cancer remains unclear, as 
other risk factors are involved. However, where smoking status was considered 
separately, the new evaluations indicate that there may be an effect of alcohol on 
pancreatic cancer independent of the effect of smoking. 
In summary: 
 Evidence from the new publications supports the conclusion that low and 
medium levels of alcohol consumption are not associated with increased 
pancreatic cancer risk, but high intakes (>50 g ethanol/day) may be 
associated with a small increase in risk. The exact role of alcohol 
consumption remains unclear. 
 Studies where smoking status was considered separately were suggestive of 
an effect of alcohol on pancreatic cancer independent of the effect of 
smoking. 
2.3 Conclusions 
In reviewing new epidemiological publications on the association of alcoholic 
beverage intake and specific cancers we noted limitations of some of the studies, 
including uncertainties in disease ascertainment and exposure assessment 
methodologies, lack of consistency between studies in reporting alcohol intake 
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levels, and lack of differentiation between never drinkers and former or ex-drinkers, 
given that many studies used a non-drinker category.  
Our findings and conclusions based on the new publications for each of the cancer 
types evaluated are summarised in Table 2. 
 
Table 2: Summary of findings from epidemiological data published since the last 
IARC review in 2009 on cancer sites considered to be associated or causally 
associated with alcoholic beverage consumption. 
Cancer site IARC opinion (IARC, 2012) 






Consumption of alcoholic beverages 
is causally related to cancer of the 
upper aerodigestive tract. Increasing 
alcohol consumption increases risk 
in a dose-dependent manner, and 
does not vary by beverage type or 
sex. 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is causally associated 
with risk of upper aerodigestive tract 
cancers. Increasing alcohol 
consumption increases risk in a 
dose-dependent manner. 
Statistically significant increased 
risks were generally observed at 
medium and high (>12.5 g 
ethanol/day) but not low alcohol 
intakes. 
Oral cavity and 
pharynx 
Consumption of alcoholic beverages 
is causally related to cancer of the 
oral cavity and pharynx. Increasing 
alcohol consumption increases risk 
in a dose-dependent manner, and 
does not vary by beverage type or 
sex. 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is causally associated 
with risk of cancers of the oral cavity 
and pharynx (combined). Increasing 
alcohol consumption increases risk 
in a dose-dependent manner. 
Statistically significant increased 
risks were observed at low, medium 
and high levels of intake. 
 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is causally associated 
with the risk of cancer of the oral 
cavity. Statistically significant 
increased risks were consistently 
observed at high alcohol intakes 
(>50 g ethanol/day), but findings 
were more variable at medium and 
low intakes. 
 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is causally associated 
with the risk of cancer of the 
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Cancer site IARC opinion (IARC, 2012) 
New publications - COC 
conclusions 
pharynx. Statistically significant 
increased risks were consistently 
observed at high alcohol intakes 
(>50 g ethanol/day), but findings 
were more variable at medium and 
low intakes. 
Larynx Consumption of alcoholic beverages 
is causally related to cancer of the 
larynx. Increasing alcohol 
consumption increases risk in a 
dose-dependent manner, and does 
not vary by beverage type or sex. 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is causally associated 
with risk of laryngeal cancer. 
Statistically significant increased 
risks were consistently observed at 
medium and high (>12.5 g 



















Consumption of alcoholic beverages 
is causally related to squamous cell 
carcinoma (SCC) of the 
oesophagus. Increasing alcohol 
consumption increases risk in a 
dose-dependent manner, and does 
not vary by beverage type or sex. 
Studies add further weight to the 
existing view that consumption of 
alcoholic beverages is causally 
associated with risk of squamous 
cell carcinoma (SCC) of the 
oesophagus. Increasing alcohol 
consumption increases risk in a 
dose-dependent manner. 
Statistically significant increased 
risks were observed at low, medium 






There is a substantial body of 
evidence that alcoholic beverage 
consumption is not associated with 
adenocarcinoma (AC) of the 
oesophagus. 
Studies add further weight to the 
view that consumption of alcoholic 
beverages is not associated with 
adenocarcinoma (AC) of the 
oesophagus.  
Female breast Consumption of alcoholic beverages 
is causally associated with the 
occurrence of cancer of the female 
breast. Cancer risk increases 
proportionately according to the 
amount of alcohol consumed, with 
an increase in risk up to 12% for 
each additional drink consumed 
regularly each day (equivalent to 
about 10 g/day). Risk does not 
appear to vary significantly by 
beverage type or smoking status. It 
is unclear whether the risk of female 
breast cancer associated with 
alcoholic beverage consumption 
varies by use of hormone-
replacement therapy or by tumour 
Studies are consistent with the view 
that alcohol consumption is causally 
associated with female breast 
cancer. Increasing alcohol 
consumption increases risk in a 
dose-dependent manner. 
Statistically significant increased risk 
was observed at low, medium and 
high alcohol intakes. 
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Cancer site IARC opinion (IARC, 2012) 
New publications - COC 
conclusions 
receptor status. 
Liver Consumption of alcoholic beverages 
is causally related to hepatocellular 
carcinoma. 
Studies are consistent with the view 
that alcohol consumption is causally 
associated with liver cancer. A 
consistently positive association was 
observed between alcoholic 
beverage consumption and liver 
cancer at high intakes. 
Colorectum Consumption of alcoholic beverages 
is causally related to cancer of the 
colorectum. Most of the evidence 
suggests that the association is with 
both cancer of the colon and rectum 
and is similar in men and women, 
but data are not entirely consistent. 
There is some evidence that risk 
may only be increased at high levels 
of intake (> 30 g/day). There is 
consistent evidence that risk does 
not differ by beverage type. The 
evidence is inconsistent as to 
whether the risk associated with 
consumption of alcoholic beverages 
differs by smoking or folate intake 
status. 
Overall, new evidence is consistent 
with the view that alcohol 
consumption is causally associated 
with colorectal cancer. The majority 
of individual cohort and case-control 
studies showed no statistically 
significant positive association 
between alcohol consumption and 
colorectal cancer, whilst some of the 
meta-analyses showed associations 
at medium and high (>12.5 or >30 g 
ethanol/day) but not low levels of 
alcohol intake. 
Pancreas Accumulating evidence that high 
alcohol intake (≥ 30 g/day) is 
associated with a small increased 
risk for cancer of the pancreas, but 
the possibility of residual 
confounding by smoking cannot be 
excluded. It is unclear whether the 
risk associated with heavy alcohol 
consumption differs by beverage 
type, smoking status or body mass 
index. 
Studies support the conclusion that 
low and medium levels of alcohol 
consumption are not associated with 
increased pancreatic cancer risk, but 
high intakes (>50 g ethanol/day) 
may be associated with a small 
increase in risk. 
 
Studies where smoking status was 
considered separately were 
suggestive of an effect of alcohol on 
pancreatic cancer independent of 
the effect of smoking. 
2.3.1. Comparison of findings from the new publications with those of the 
IARC review in 2009 
We consider that the new epidemiological papers published since the most recent 
IARC review in 2009 (IARC, 2012) add further weight to the view that consumption of 
alcoholic beverages is causally associated with risk of cancers of the upper 
aerodigestive tract including the oral cavity and pharynx, larynx and oesophageal 
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squamous cell carcinoma (SCC), and the female breast, the liver, and the 
colorectum. 
The new information on alcohol consumption and pancreatic cancer risk also 
supports the conclusion made by IARC in 2009 that there is accumulating evidence 
that consumption of alcoholic beverages at high levels is associated with increased 
risk of cancer of the pancreas.  
The new evidence supports the opinion of IARC that consumption of alcoholic 
beverages is not associated with oesophageal adenocarcinoma (AC). 
The new publications support the opinion of IARC that risk of cancer does not 
depend on the type of alcoholic beverage consumed. A number of studies evaluated 
cancer risks associated with drinking specific beverage types (e.g., wine, beer, or 
spirits). Overall, it was not possible to identify any specific beverage type that had a 
specific effect at any of the cancer sites considered. 
2.3.2 Levels of alcohol consumption associated with risk of cancer 
In looking at the new evaluations, we have identified that for some cancers intake of 
alcohol at all levels of consumption increases risk, whereas at other cancer sites 
there is only good evidence of an effect of alcoholic beverage consumption above 
certain levels of intake: 
 At low, medium and high levels of alcohol intake, there is a statistically 
significant increased risk at the following cancer sites:  
- oral cavity and pharynx (combined)  
- oesophagus (squamous cell carcinoma)  
- female breast 
 At medium and high levels of alcohol intake (i.e. generally at intakes >12.5 
g ethanol/day, or > approximately 1.5 UK units/day), there is a statistically 
significant increased cancer risk for the following cancer sites:  
- larynx  
- colorectum 
 At high levels of alcohol intake (i.e. generally at intakes >50 g ethanol/day, 
or > approximately 6 UK units/day) there is a statistically significant increased 




3 EVIDENCE FOR THE EFFECTS OF BINGE DRINKING ON CANCER RISK 
At the start of our review, we recognised the growing interest in the effects of 
drinking large amounts of alcohol over a short time period, or ‘binge drinking’ (HM 
Government, 2012). The UK Opinions and Lifestyle Survey (ONS, 2015), similar to 
the predecessor surveys, considers people to have binged if they consumed more 
than 8 units (>64 g ethanol) for men or 6 units (>48 g ethanol) for women (i.e. more 
than double the current guidelines) on their heaviest drinking day in the last week. 
We decided, where possible, to specifically investigate whether the new publications 
(see section 2.1) provided data on whether binge drinking affects cancer risk.  
The vast majority of the studies reviewed evaluated the effect of total alcohol intake 
on cancer risk, without necessarily identifying any specific pattern of drinking 
amongst the participants. The surveys used in the epidemiology studies would often 
use a questionnaire-based approach to estimate exposure and then either use a 
weekly intake (which if not already done we averaged to a daily intake) or the 
heaviest drinking day in the last week without evaluating on how many days the 
participant had consumed alcohol.  
One of the studies we reviewed did report consideration of the effect of binge 
drinking on pancreatic cancer risk in men, where binge drinking was defined as the 
irregular consumption of >5 drinks/day (>70 g ethanol/day), analysed separately 
from the usual drinking pattern. This case-control study also looked at how often 
binge drinking occurred, and over how many years binge drinking had occurred 
(Gupta et al, 2010)., There was a statistically significant increased risk of pancreatic 
cancer increased in men with a ‘usual’ alcohol intake above 22 drinks per week 
compared with men consuming <1 drink/month: 
Drinks/week  g ethanol/day RR 95% CI 
22-35    >42-70  1.9 1.0-3.7 
>35   >70   2.2 1.1-4.6 
For men with a lifetime history of binge drinking at least once per month, the RR was 
3.5 (95% CI 1.6-7.5) versus men consuming <1 drink/month. Risk was associated 
with increasing average number of drinks consumed during a drinking session and 
also with increasing number of years of binge drinking. Even where frequency of 
binge drinking was once a month or less, it was still associated with elevated risk 
(OR=4.3, 95% CI 1.8-10) compared with a lifetime alcohol consumption of none or 
<1 drink/month. 
Based on the Gupta paper, there does seem to be potential for an effect of binge 
drinking on lifetime risk of cancer, in this instance pancreatic cancer, but further 
evidence is required for the different cancer sites and from more studies to 
determine whether there is a specific effect of binge drinking over and above that of 
total lifetime alcohol consumption.  
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We note that there are a number of similar, but not identical, definitions of binge 
drinking available (NHS choices, Alcohol Concern, and Public Health Agency, 
Northern Ireland), which consider both number of units but also the time frame over 
which drinking occurs. The definition of binge drinking used by the ONS (ONS, 
2015), that people have binged if they consumed more than double the current 
guidelines of 8 units (64 g ethanol) for men or 6 units (48 g ethanol) for women on 
their heaviest drinking day in the last week, is essentially the same means by which 
heavy drinking appears to us to be identified, and therefore there may be some 
overlap between effects reported as associated with heavy drinking and those that 
may be associated with binge drinking. In addition, we also note the recent paper on 
atypical and special occasion drinking compared to national survey information 
(Bellis et al., 2015).   
We consider that, while there is an overlap between binge drinking and regular 
heavy drinking, it would be helpful if both survey data on consumption trends and 
epidemiology studies express clearly their definition of binge drinking, how it has 
been assessed and the intake category it is being compared to.  
To evaluate the potential effects of binge drinking on cancer risk, we recommend 
agreement of a clear and measureable definition of binge drinking. It would also be 
helpful if studies provide clear data on the following aspects: background average 
drinking level, without binge sessions; the time frame of individual binge drinking 
sessions (hours or based on a day’s consumption or over a couple of days); amount 
of alcohol consumed to classify as a binge; frequency of binge episodes; number of 
years of binge drinking; and how long ago binge drinking may have stopped. 
In summary: 
 There is very little evidence from the new publications regarding the effect of 
drinking large amounts of alcohol on a single occasion (‘binge drinking’). 
Most of the new evaluations looked at the effect of total alcohol intake over a 
period such as a week or a month on cancer risk, and not the amount of 
alcohol consumed per drinking episode. 
4 INTERACTION BETWEEN ALCOHOL AND GENOTYPE IN CANCER RISK 
In its latest evaluation of alcohol and cancer, IARC noted that there is sufficient 
epidemiological evidence showing that people who are deficient in the oxidation of 
acetaldehyde to acetic acid and subsequently acetate have a substantially increased 
risk of developing alcohol-related cancers, in particular of the oesophagus and the 
upper aerodigestive tract (IARC, 2012). IARC noted that the available 
epidemiological data suggest a positive association between the alcohol 
dehydrogenase (ADH) genotype ADH1B*1/*1 and cancer of the oesophagus, and 
cancers of the upper aerodigestive tract combined, with insufficient data to draw 
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conclusions regarding this genotype for other cancer sites. IARC considered that 
there were insufficient data to draw conclusions regarding the ADH1C genotype and 
cancer at any site. Regarding the aldehyde dehydrogenase genotype, ALDH2, IARC 
noted that there is evidence for a contribution of heterozygous ALDH2 genotype to 
the development of alcohol-related cancer in the upper aerodigestive tract, 
oesophagus and oropharyngolarynx, particularly the hypopharynx, and that there are 
some data suggestive of association of heterozygous ALDH2 genotype with 
individual sub-sites of the oral cavity, oropharynx and larynx, but that evidence for 
other cancers was inconclusive. The IARC evaluation cautioned that data regarding 
genetic susceptibility can be difficult to interpret and require careful evaluation, 
particularly when identified susceptibility genes have no or unknown functional 
characterisation (IARC, 2012). It was noted that for polymorphisms affecting alcohol 
or acetaldehyde metabolism people may be heterozygotes for some of the alleles 
encoding more or less active forms that could both promote and inhibit the 
development of cancer. Also, heterozygotes for some alleles that enhance alcohol 
oxidation or inhibit acetaldehyde metabolism may avoid drinking alcohol and so be 
protected from the harmful effects. It is, thus, essential when looking at these gene 
polymorphisms and cancer to control for differences in alcohol drinking.  
With respect to the potential mutagenicity of alcohol or its metabolites, the UK 
independent advisory Committee on Mutagenicity of Chemicals in Food, Consumer 
Products and the Environment (COM) recently concluded that, overall, studies 
investigating genetic polymorphisms in key enzymes involved in ethanol metabolism 
have suggested that the ALDH2-deficient genotype is likely to contribute to the 
overall mutagenic potential of alcohol, whilst at present data are inconsistent or 
lacking for genetic polymorphisms of other enzymes (COM, 2016). 
Amongst the new epidemiological studies that we reviewed, a small number of these 
evaluated cancer risk associated with variant genotypes and alcoholic beverage 
consumption. The findings support the conclusions of IARC that variations in ADH1B 
and ALDH2 genotypes may affect risk of upper aerodigestive tract and oesophageal 
cancers (Ding et al., 2010; Tanaka et al., 2010; Hakenewerth et al., 2011; Tsai et al., 
2014) and that ALDH2 genotypes also affect oral cavity and pharyngeal cancer risk 
(Matsuo et al., 2012). In addition, an analysis from the European ARCAGE study 
indicated an association between homozygosity for an ADH1C variant and alcohol-
associated upper aerodigestive tract cancer (Canova et al., 2010). A few studies 
suggested association among ADH1B and ADH1C genotypes and alcohol intake 
and risk of breast (Benzon Larsen et al., 2010; McCarty et al., 2012) or colorectal 
(Bongaerts et al., 2011; Ferrari et al., 2012) cancers. One study in Korea showed an 
interaction between alcohol consumption and MTHFR genotype in colorectal cancer 
risk (Kim et al., 2012).  
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In summary: 
 The new publications indicate some evidence for alcohol consumption and 
genotype interactions in cancer risk for ADH1B, ALDH2 and ADH1C genes 
and upper aerodigestive tract cancers, ADH1B and ADH1C genes and 
breast or colorectal cancers, and the MTHFR gene and colorectal cancer. 
5 BURDEN – ALCOHOL ATTRIBUTABLE RISK 
As part of this review, the Committee looked at a number of publications estimating 
the burden of cancer attributable to alcohol in the UK, by applying relative risk data 
from epidemiological studies to UK survey data, and other papers discussing 
methodological aspects of undertaking such estimates. As these papers provided 
estimates based on recent data, we agreed to review the approaches used, rather 
than undertake our own de novo estimation.  
Of the five papers considered which made estimates of burden of cancer attributable 
to alcohol consumption in the UK, four considered all the 6 cancer sites for which 
IARC concluded alcohol consumption has a causal association. The last paper 
focused on oral cavity and pharyngeal cancer. The approaches by the different 
authors used broadly similar methodology to calculate the alcohol attributable 
fraction. The main differences were choice of: 
 The relative risk estimates from epidemiological studies, and  
 The alcohol consumption data from surveys, including whether and how this 
was adjusted to address the differences between reported consumption from 
the surveys and alcohol sales data. 
The estimated alcohol attributable fractions for each of the papers are given in Table 
3 (see next page) with the relative risk and alcohol consumption estimates used in 
each. 
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Table 3: Overall alcohol attributable fractions for the UK or England determined in 
the literature by cancer site along with the sources of data for the risk ratios and 
alcohol consumption levels used 
 




Schutze et al, 
2011 
Jones et al, 
2008 
Meier et al, 
2013 
M F M F M F M F M F 
Oral cavity 
and pharynx 







Oesophagus 25 11 58 43 25 12 - - 
Larynx 27 12 37 24 28 14 - - 
Colorectal 16 7 16 12 14 5 4 2 - - 
Liver 11 5 15 11 33 13 13 6 - - 
Breast - 6 - 13 - 5 - 6 - - 
 
Source of, and approximate exposure-response 
(excess risk per g alcohol per day) 
Oral cavity 
and pharynx 
Corrao et al., 
2004: ~0.019; 
0.04 at 50 g/d 
Tramacere et 
al., 2010:  
0.029 at 10 g/d; 
















Corrao et al., 
2004: ~0.013; 
0.019 at 50 g/d 
Islami et al., 
2011: ~0.05 




Corrao et al., 
2004: ~0.014; 
0.02 at 50 g/d 
Islami et al., 
2010: 0.017 at 
10; 0.27 at 100 
Corrao et al., 
2004 
- - 
Colorectal Various: 0.008 












Corrao et al., 
2004: 0.002 at 




Corrao et al., 
2004: 0.006 











































23.6 11.6 32.9 17.3 35.2 17.6 22.5 12.6 - - 
 
In considering the available attributable fractions, we noted that the Jones and Bellis 
(2014) paper was an update of the Jones et al. (2008) paper and therefore we 
decided to focus on the more recent paper.  
One paper from the European Prospective Investigation into Cancer and Nutrition 
(EPIC) (Schütze et al, 2011), gave attributable fractions that were somewhat 
different to the others. This was because: 1) the relative risk data came only from the 
EPIC study, whereas the other studies used similar values for the relative risk 
(depending on the data available at the time of the analysis); 2) the consumption 
data came from WHO rather than the UK Office for National Statistics, which was 
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used in the other studies, with varying adjustment to account for under-reporting in 
surveys compared to sales data. While the Schütze et al. (2011) paper came from 
the well regarded EPIC study, due to the different data used and because of the 
number of assumptions made in the analysis, we did not use the results from this 
paper in our estimation of number of alcohol attributable cancers below. 
The Meier et al (2013) paper focussed on oral cavity and pharyngeal cancer and 
investigated the effects of different approaches to adjusting survey data to bring it 
more in line with sales data. Therefore, we did not use these data in our estimation 
of number of alcohol attributable cancers.  
A number of aspects that could be adjusted for, and sensitivity analyses that had 
been undertaken, were reviewed by the Committee and further information is 
available in the discussion papers considered (CC/2014/18 and CC/2015/07). 
Only one of the papers (Parkin, 2011) took account of any latency period for 
induction of alcohol-related cancer, by using consumption data from the period 10 
years earlier. While this addresses the possibility that risk of cancer relates more 
closely to earlier rather than current consumption, it is likely that the relative risks in 
epidemiology studies encompass some variation in habits over time and also relate 
to recent rather than lifetime drinking (Darnton 2015, personal communication). 
There is a mismatch between self-reported alcohol consumption from surveys and 
data on alcohol sales, with sales data indicating higher per capita consumption. A 
number of the papers estimating the UK attributable fraction by applying relative 
risks from epidemiological studies to UK survey data adjust the alcohol consumption 
survey data to reflect this discrepancy with sales data in their analyses. The paper by 
Meier et al (2013) focused on investigating the effects of different approaches to 
adjusting survey data to bring it more in line with sales data using oral cavity and 
pharyngeal cancer as an example. However, Parkin (2011) suggests that the under-
reporting of alcohol consumption in surveys can similarly be considered to occur 
from self-reporting of alcohol consumption in the epidemiology studies from where 
the relative risk estimates can be derived and thus adjusting for this may be 
inappropriate. Parkin did not therefore adjust his estimates which are substantially 
lower than other estimates (Table 3). In contrast, Jones and Bellis (2014) do adjust 
the alcohol consumption rates to take account of under-reporting. In doing so, they 
note that adjustment for under-reporting based on per capita consumption brings 
further assumptions, such as that under-reporting is evenly distributed across 
different population groups, e.g. age and sex groups, and that it applies evenly 
across the different alcohol consumption levels. Overall, we recognise the need for 
some adjustments to be made, but there needs to be recognition of the uncertainties 
associated with uprating and the further assumptions that it brings. Therefore, in this 
analysis we have considered one paper that does adjust (Jones and Bellis, 2014) 
and one paper that does not adjust (Parkin, 2011) for under-reporting of alcohol 
consumption in estimating the alcohol attributable fraction. 
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For the reasons discussed in this section, we have used the all-age overall 
attributable fractions from Parkin (2011) and Jones and Bellis (2014) and applied 
these to the 2013 Cancer Registry incidence statistics, to estimate the alcohol 
attributable number of cancers (Table 4, see next page). Using the attributable 
fractions from Parkin (2011) results in an estimate of 4% of all new cancers in the UK 
in 2013 being attributable to alcohol consumption, while using the Jones and Bellis 
(2014) attributable fractions results in an estimate of 6% of new cancers being 
attributable to alcohol consumption. 
In summary: 
 We looked at available papers assessing the burden of alcohol consumption 
on cancer incidence in the UK in order to get a general idea of the 
involvement of alcohol in cancer burden. The evaluations used broadly similar 
approaches and most used similar datasets to underpin the calculations, but 
there were differences in adjustment of the data. As a result we did not 
consider it necessary to undertake our own de novo estimation.  
 Of the adjustments made, the most common was to account for the under-
reporting of alcohol consumption in surveys as compared to alcohol sales, 
and though this also introduces uncertainty, we conclude that some 
adjustment is appropriate.  
 Findings from the two most appropriate studies on UK populations indicate 
that 4-6% of all new cancers in the UK in 2013 were caused by alcohol 
consumption.   
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Table 4: Alcohol attributable numbers of cancers diagnosed in 2013 by cancer site 1 
































































Oral cavity & 
pharyngeal 
cancer 
5,713 37 2,114 42 2,399 2,867 17 487 34 975 8,580 2,601 3,374 
Laryngeal 
cancer 
1,915 27 517 37 709 400 12 48 24 96 2,315 565 805 
Oesophageal 
cancer 




     53,339 6 3,200 13 6,934 53,339 3,200 6,934 
Liver  
cancer 
3,466 11 381 15 520 1,907 5 95 11 210 5,373 476 730 
Colorectal 
cancer 


































179,093  5%  6% 172,485  3%  7% 351,578 4% 6% 
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6 EVALUATION OF SOME INDIVIDUAL META-ANALYSES REPORTING 
POTENTIAL INVERSE RELATIONSHIPS BETWEEN ALCOHOL AND SOME 
CANCER TYPES 
We reviewed some individual meta-analyses published since the most recent IARC 
review of alcohol and cancer in 2009, which evaluated the relationship between 
alcoholic beverage intake and the risks of kidney cancer, Hodgkin lymphoma, non-
Hodgkin lymphoma, and extra-hepatic bile system cancer. These individual 
publications were reviewed because they came to our attention due to the 
suggestion that alcohol consumption results in reduced risk for these cancers. They 
were not identified in the same way as the information on the cancer sites above in 
section 2, nor have any further literature searches been carried out to identify other 
available data on these cancer sites. These data are summarised in Table 5. 
6.1 Kidney 
In 2013, there were 11,023 new cases (6,885 in men and 4,138 in women) of kidney 
cancer and 3,785 deaths (2,335 in men and 1,450 in women) from kidney cancer in 
the UK. 
IARC (2012) concluded that there is no causal association between consumption of 
alcoholic beverages and cancer of the kidney. We reviewed two meta-analyses 
published since the latest IARC evaluation that showed an inverse relationship 
between alcohol consumption and renal cell carcinoma risk. The meta-analysis of 
Song et al. (2012) indicated a combined RR of 0.73 (95% CI 0.67-0.79) for top 
versus bottom alcohol intake categories. The meta-analysis of Bellocco et al. (2012) 
showed a negative association between alcohol consumption and renal cell 
carcinoma for low and medium alcohol intakes, whilst results were not statistically 
significant for high intakes, compared with non-drinkers: 
   g ethanol/day RR 95% CI 
   0.01-14.49  0.90 0.83-0.97 
   12.5-49.9  0.79 0.71-0.88 
   ≥50   0.89 0.58-1.39 
We note that in the small number of studies included in these meta-analyses that 
considered high levels of alcohol consumption, the negative association levelled off 
at intakes of 20-25 g ethanol/day. 
We discussed the possible mechanisms by which alcohol might reduce the risk of 
kidney cancer. While it is not clear what mechanisms could be involved, it was 
suggested that the development of tumours might be influenced by altered fluid 
consumption impacting on urine production.  
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6.2 Non-Hodgkin lymphoma and Hodgkin lymphoma  
There were 13,395 new cases (7,253 in men and 6.142 in women) of non-Hodgkin 
lymphoma (NHL) and 1,951 new cases (1.097 in men and 854 in women) of Hodgkin 
lymphoma (HL) in the UK in 2013. In the same year, there were 4,666 deaths (2,559 
in men and 2,107 in women) from NHL and 294 deaths (164 in men and 130 in 
women) from HL. 
IARC (2012) concluded that there is evidence suggesting a lack of carcinogenicity of 
alcoholic beverages and NHL, noting that the results from some cohort studies and 
very large case-control studies showed an inverse association or no association. 
IARC (2012) did not state a conclusion regarding alcohol consumption and HL, but 
did note that there is a consistent inverse association in case-control studies 
investigating ever-alcohol consumption and risk for HL. We reviewed two meta-
analyses (one for NHL and one for HL) published since the most recent IARC 
evaluation that suggested a decrease in risk of these cancer types among people 
consuming alcohol as compared with non-drinkers. The meta-analysis of Tramacere 
et al. (2012b) showed an overall RR for NHL of 0.85 (95% CI 0.79-0.91) and that of 
Tramacere et al. (2012c) an overall risk for HL of 0.70 (0.60-0.81) in drinkers versus 
non-drinkers.  However, breakdown by study type tended to show significant findings 
for case-control but not cohort studies. A statistically significant dose-response was 
not observed for either cancer type and the authors suggested caution in 
interpretation of the findings.  
We have concerns about the consistency of the classification of cancers of this type 
and the confounding effect of diverse lymphoma types. In addition, there is no 
immediately obvious mode of action that could explain the association.  
6.3 Extra-hepatic bile system cancer 
There were 1,932 new cases (835 in men and 1,097 in women) of extra-hepatic bile 
system cancer England and Scotland6 in 2013, and 790 cancer deaths (269 in men 
and 521 in women) in England, Wales and Scotland7. 
IARC (2012) noted that it is not possible to draw any conclusion concerning the 
consumption of alcoholic beverages and risk of cholangiocarcinoma (which includes 
intra- and extra-hepatic bile system cancers). We reviewed a meta-analysis 
published since the last IARC evaluation that showed an inverse association of 
alcohol consumption and extra-hepatic bile system cancer. This is a rare cancer site 
with a large number of potential risk factors. The meta-analysis of Kan et al. (2011) 
                                                          
 
6
 Wales and Northern Ireland data not available 
7
 Northern Ireland data not available 
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showed an overall OR for extra-hepatic bile system cancer of 0.82 (95% CI 0.72-
0.94) for alcohol drinkers versus non-drinkers. The OR was increased in high-level 
drinkers (≥80 g ethanol/day) versus non-drinkers, but the results were not statistically 
significant (OR=1.58, 95% CI 0.97-2.57). The authors noted that there may be a 
threshold of alcohol consumption for risk of extra-hepatic bile system cancer, though 
this would need to be verified. 
6.4 Conclusions on studies reporting potential inverse effects 
A summary of the IARC conclusions for these cancer sites and our conclusions 
based on these individual papers is presented in Table 5.  
Table 5: Summary of findings from some individual epidemiological meta-analyses 
published since the last IARC review in 2009, reporting inverse associations of 
alcoholic beverage consumption with some cancer types. 
Cancer site IARC opinion (IARC, 2012) COC observations 
Kidney There is no causal association 
between the consumption of alcoholic 
beverages and cancer of the kidney. 
Two meta-analyses (Song et al., 
2012; Belloco et al., 2012) indicated 
an inverse association between 
alcohol consumption and renal cell 





There is evidence suggesting a lack 
of carcinogenicity of alcoholic 
beverages and non-Hodgkin 
lymphoma. The results from some 
cohort studies and very large case-
control studies have shown an 
inverse association or no association. 
In general there is no difference in 
findings for specific beverage types. 
The meta-analysis of Tramacere et 
al. (2012b) indicated a decrease in 
risk of non-Hodgkin lymphoma in 
people consuming alcohol compared 
with non-drinkers. A statistically 




There is a consistent inverse 
association in case-control studies 
investigating ever-alcohol 
consumption and risk for Hodgkin 
lymphoma, with no significant 
different between alcoholic beverage 
types. 
The meta-analysis of Tramacere et 
al. (2012c) indicated a decrease in 
risk of Hodgkin lymphoma in people 
consuming alcohol compared with 
non-drinkers. A statistically significant 
dose-response was not observed.  
Extrahepatic 
bile system 
It is not possible to draw conclusions 
regarding the consumption of 
alcoholic beverages and the risk of 
cholangiocarcinoma (i.e. intra- and 
extra-hepatic bile system cancer).  
The meta-analysis of Kan et al.  
(2011) indicated an inverse 
association of alcohol consumption 
and extra-hepatic bile system cancer. 
Compared with non- or low-level 
drinkers, risk was reduced for 
moderate drinkers but increased for 
heavy drinkers. 
36 
We note that one of the limitations across all these studies is the comparison 
category. In some instances the non-drinker is the comparator, though it is possible 
that this would include people who stopped drinking as a result of their diagnosis. It 
is also possible that the characteristics of the people in the non-drinker category are 
different to those in the drinking category, which could confound the results. Finally, 
in some studies the comparison group is non- and low-intake drinkers, making it 
difficult to comment on the effect of low-level alcohol consumption.  
We note that associations such as those suggested by these meta-analyses are 
sometimes stated as showing a protective effect, in this instance of alcohol 
consumption for these cancers. However, we have not reviewed any mechanistic 
information which might explain any protection. Although the meta-analyses may be 
suggestive of an inverse relationship with lower levels of alcohol consumption, the 
underlying mechanisms are unclear, thus limiting the interpretation of these findings. 
Any positive effects are outweighed by the risks associated with alcohol 
consumption. 
In summary: 
 Overall, it is difficult to draw any firm conclusions from these meta-analyses 
on inverse effects of alcohol consumption for these cancers, which 
nevertheless support the conclusions of IARC that alcohol consumption is not 
causally associated with these cancers. 
7 EFFECT OF CESSATION OF ALCOHOL CONSUMPTION ON CANCER 
RISK. 
As part of our review of alcohol and cancer risk, we felt that it was important to 
consider risk reduction strategies. Therefore, we reviewed the available evidence on 
the impact of cessation of alcohol consumption on cancer risk for the cancer sites 
where IARC has concluded that alcohol consumption has a causal association. 
Evidence on the effect of cessation of alcohol consumption was only identified for 
upper aerodigestive tract cancers and liver cancer (for further information, see 
discussion papers CC/2014/04 and CC/2014/13). Much of the evidence was based 
on case-control studies and relied on subjects providing a history of their exposure 
rather than on prospective follow-up of a cohort of people. It is not always clear why 
people stopped drinking, but potential reasons include health concerns or 
deteriorating health, which could influence the results, especially for the years 
immediately after cessation of alcohol consumption. The comparison groups varied 
between studies, in some cases comprising people who had never consumed 
alcohol, whilst in other studies comparison was made with current drinkers. 
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Overall, the data from a number of studies examining the effects of alcohol cessation 
on the risk of upper aerodigestive tract and liver cancers demonstrate a reduction in 
risk following long-term abstention. However, the results are not consistent across all 
studies and the magnitude of effect varies between studies. In some studies an initial 
increase in risk or a trend to an initial increase in risk was observed, followed by 
decreased risk in the longer term, while other studies found a decrease in risk 
immediately after cessation. The observation of an initial increase in risk following 
cessation was particularly evident for oesophageal cancer and studies conducted in 
European subjects. This apparent increase in cancer risk immediately after cessation 
of alcohol consumption may be a consequence of cessation by people who were 
already becoming ill, i.e. the sick-quitter phenomenon. This is clearly different to the 
benefits of smoking cessation, where the risk starts to decrease shortly afterwards.  
There is also a need for caution because most studies were case-control studies 
with small numbers of subjects included, especially at longer time points.  
The evidence on cessation of alcohol consumption shows that it takes a long time for 
risks to fall to the level of the never drinker. The time period required for risks of 
upper aerodigestive tract and liver cancers for former drinkers to fall to those of 
never drinkers appears to be in the range of 20 years or more.  
We considered whether it would be possible to comment on the impact of reducing 
alcohol consumption rather than complete cessation on cancer risk, but no data were 
identified to assess this. However, it is plausible that there would be a benefit of 
reducing consumption, as the risk of cancer at the sites assessed tends to be lower 
at lower alcohol intake.  
In summary: 
 The effect of long-term abstention from alcohol on cancer risk has been 
investigated for upper aerodigestive tract and liver cancers. These studies 
indicated a reduction in risk following long-term abstention, although risks may 
take many years, in the range of 20 years, to fall to the level of never drinkers. 
 While there are no studies investigating reducing alcohol consumption, it is 
plausible that reducing consumption would lead to a reduction in cancer risk. 
8 POTENTIAL MECHANISMS BY WHICH ALCOHOL MAY INCREASE THE 
RISK OF CANCER 
IARC (2012) concluded that ethanol is the principal ingredient that renders alcoholic 
beverages carcinogenic, and that in the body ethanol is converted by ADH and 
CYP2E1 enzymes to acetaldehyde, which is cytotoxic, genotoxic, mutagenic and 
clastogenic, and has been shown to be carcinogenic in experimental animals. 
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Evidence for the key roles of ethanol and acetaldehyde is strengthened by the 
associations observed between different forms of cancer and polymorphisms in 
ethanol and acetaldehyde metabolism (see Section 4). Potential ethanol-related 
mechanisms of carcinogenesis include oxidative stress (which has been associated 
with ethanol-induced carcinogenesis in many organs, such as breast, liver and 
pancreas), cirrhosis (hepatocellular injury leading to enhanced fibrogenesis in the 
liver), interactions with tobacco smoke (especially for oro-pharyngeal and 
oesophageal cancers), effects on sex hormones (such as increased oestrogen and 
androgen levels associated with alcohol intake in women that may contribute to the 
development of breast cancer) and effects on folate metabolism (e.g. the association 
of alcoholic beverage consumption, folate deficiency and colorectal cancer). A role of 
acetaldehyde has been demonstrated by associations of inactive ALDH alleles with 
oesophageal cancer in East Asian populations and of ADH1B polymorphisms and 
upper aerodigestive tract cancers (IARC, 2012). 
In our previous evaluation of the association of alcohol and breast cancer, we 
concluded that it is not known precisely how drinking alcohol can lead to breast 
cancer. The most likely explanation is that drinking alcohol can produce biochemical 
effects in the liver (such as changes to oestrogen metabolism and effects on growth 
factors) which, if alcohol drinking is prolonged (i.e. over decades), could lead to 
breast cancer (COC, 2004). 
As part of this review we asked the Committee on Mutagenicity of Chemicals in 
Food, Consumer Products and the Environment (COM) to update its 2000 review on 
the evidence regarding the potential for alcoholic beverages to induce mutagenicity 
in vivo. The COM considered the available evidence to May 2014 on the 
mutagenicity of alcohol and its primary metabolite, acetaldehyde, from in vitro and in 
vivo studies and studies in humans following consumption of alcoholic beverages 
(see MUT/2014/05). Studies investigating genotoxic and mutagenic effects arising 
from the consumption of alcoholic beverages in humans did not consistently account 
for relevant confounding factors (e.g. smoking, BMI, or nutritional intake). Other 
quality issues limited the reliability of the study findings (e.g. small sample sizes, 
poor exposure assessments). The COM acknowledged the emergence of additional 
studies on DNA adduct formation in humans, and studies reporting the influence of 
polymorphisms in enzymes involved in alcohol metabolism, particularly in relation to 
induction of micronuclei. However, it considered that the poor quality of most of 
these studies prevented any useful conclusions from being drawn. The COM noted 
that a number of studies have implicated the formation of acetaldehyde-specific DNA 
adducts and inter-strand DNA crosslinks as upstream events in the genotoxicity of 
alcohol. However, the poor reliability of data available from in vivo studies on the 
genotoxicity of ethanol and from studies in humans meant it was not possible to draw 
any definitive conclusions on the genotoxicity of alcohol per se.  Acetaldehyde is 
widely accepted as being genotoxic in vitro and in vivo, when administered directly. It 
was agreed that the recent in vitro data on acetaldehyde added further strong 
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evidence for the genotoxicity of this compound, particularly with regard to generation 
of acetaldehyde-specific DNA adducts and induction of micronuclei in mammalian 
cells at concentrations of acetaldehyde realistically achievable from alcoholic 
beverage consumption. It was concluded that acetaldehyde remains the metabolite 
of most concern with respect to the genotoxic effects of alcohol. However, there is 
uncertainty as to whether such effects occur as a result of its production in vivo 
following metabolism of ethanol. Studies examining the potential mutagenic 
mechanisms of ethanol and acetaldehyde were evaluated. Data suggest that 
multiple modes of action contribute to the overall genotoxicity of ethanol.  
The COM also considered a paper reviewing the hypothesis that associates the 
mutagenic and carcinogenic mode of action of alcohol in the liver with the generation 
of reactive oxygen species (ROS) and the role of CYP2E1 in this process (see 
MUT/2015/02). Alcohol consumption can result in the formation of ROS in the liver 
either via inflammatory-mediated processes or oxidative metabolism. ROS have the 
potential to generate lipid peroxidation products, which in turn may yield mutagenic, 
exocyclic DNA etheno adducts (e.g. N6-etheno-2’-deoxyadenosine, εdA; N4-etheno-
2’deoxycytidine, εdC). Ethanol consumption also results in the induction of CYP2E1, 
primarily in the liver but also in extra-hepatic tissues such as the oesophagus and 
intestine. It is suggested that this induction enhances the metabolism of alcohol to 
acetaldehyde and the generation of ROS, and accordingly increases the associated 
likelihood of adduct formation. A correlation between CYP2E1 levels and DNA 
etheno adducts has been demonstrated in animal models and in humans. However, 
an association between specific CYP2E1 alleles and alcoholic liver damage or 
alcohol-induced carcinogenesis in humans is not well defined. Overall the COM 
agreed that the hypothesis that alcohol-induced oxidative stress is of importance in 
the pathogenesis of alcohol-induced liver injury and carcinogenesis was plausible. 
There is some evidence to support this premise in humans following alcohol 
consumption. However, more work would be required in this complicated area before 
definitive conclusions could be drawn (COM, 2015). 
In summary: 
 Ethanol is the principal ingredient that renders alcoholic beverages 
carcinogenic. There are probably several different mechanisms by which 
ethanol causes cancer, and different mechanisms may be involved in the 
development of different cancer types. These include metabolism to 
acetaldehyde, oxidative stress, damage to cells in the liver leading to 
cirrhosis, interaction with other chemicals such as tobacco smoke, effects on 
sex hormones, and effects on vitamins and minerals in the body. 
9 SUMMARY 
1. The World Health Organisation's International Agency for Research on 
Cancer (IARC) has concluded that there is sufficient evidence in humans for the 
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carcinogenicity of alcohol consumption. IARC last reviewed the carcinogenicity of 
alcoholic beverages in 2009, concluding that alcohol consumption causes cancers of 
the oral cavity and pharynx, larynx, oesophagus (squamous cell carcinoma), 
colorectum, liver (hepatocellular carcinoma) and female breast, and that an 
association has been observed between alcohol consumption and cancer of the 
pancreas (IARC, 2012). 
2. We have carried out an updated review of epidemiological evaluations 
published since the IARC review in 2009, which investigated the association of the 
consumption of alcoholic beverages with these cancers. The findings reported in 
these new publications add further weight to the view that consumption of alcoholic 
beverages is causally associated with risk of cancers of the oral cavity and pharynx, 
larynx, oesophagus (squamous cell carcinoma), female breast, liver, and colorectum. 
The new evidence adds further weight to the conclusion of IARC that alcohol 
consumption is associated with cancer of the pancreas, though the role of alcohol in 
pancreatic cancer is unclear. The new evidence also supports the opinion of IARC 
that consumption of alcoholic beverages is not associated with oesophageal 
adenocarcinoma. 
3. The new publications show a statistically significant increase in cancer risk: 
 At low, medium and high levels of alcohol intake for cancers of the oral 
cavity and pharynx (combined), oesophagus (squamous cell carcinoma) and 
female breast 
 At medium and high levels of alcohol intake (i.e. generally at intakes >12.5 g 
ethanol/day, or > approximately 1.5 UK units/day) for cancers of the larynx 
and colorectum 
 At high levels of alcohol intake (i.e. generally at intakes >50 g ethanol/day, or 
> approximately 6 UK units/day) for cancers of the liver and pancreas. 
4. We note limitations of some of the studies that we reviewed, including 
uncertainties in disease ascertainment and exposure assessment methodologies, 
lack of consistency between studies in reporting alcohol intake levels, and lack of 
differentiation between never drinkers and former or ex-drinkers in ‘non-drinker’ 
reference categories.  
5. There is very little evidence from the new publications regarding the effect of 
drinking large amounts of alcohol on a single occasion. Most of the new evaluations 
looked at the effect of total alcohol intake over a period such as a week or a month 
on cancer risk, and not the amount of alcohol consumed per drinking episode.  
6. The new publications support the conclusion that all types of alcohol increase 
the risk of cancer. This is consistent with the hypothesis that it is the ethanol in 
alcoholic beverages, and the associated acetaldehyde, that is carcinogenic, and this 
is further supported by new publications that reported association of the risk of some 
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alcohol-associated cancers with specific variants of genes encoding enzymes 
involved in alcohol and acetaldehyde metabolism. 
7. We looked at a number of publications estimating the burden of cancer 
attributable to alcohol in the UK and others discussing methodological aspects of 
undertaking such estimates. We conclude that the available papers assessing the 
burden of alcohol consumption on cancer incidence in the UK use broadly similar 
approaches and most use similar datasets to underpin the calculations, but there are 
differences in adjustment of the data. As a result we did not consider it necessary to 
undertake our own de novo estimation. Of the adjustments made, the most common 
was to account for the under-reporting of alcohol consumption in surveys as 
compared to alcohol sales. Using the two most appropriate available studies 
produces estimates that 4-6% of all new cancers in the UK in 2013 were caused by 
alcohol consumption. 
8. We also discussed the findings of five individual meta-analyses that indicate 
that alcohol consumption results in reduced risk for some cancers. Several factors 
limit the drawing of firm conclusions from these studies. However, we conclude that 
they support the opinion of IARC that alcohol consumption is not likely to be causally 
associated with kidney cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, or 
extra-hepatic bile system cancer. 
9. To assess whether the risk of cancer from drinking alcohol can be reduced, 
we performed a search for all published studies that investigated the effects of 
alcohol cessation on cancer risk. Data were identified for upper aerodigestive tract 
and liver cancers. These studies indicated a reduction in risk following long-term 
abstention, although risks took several years, in some cases 20 years or more, to fall 
to the level of never drinkers. Some studies showed an initial increase in risk after 
cessation, followed by decreased risk in the longer term, which may be an effect of 
cessation by people who were already becoming ill.  
10 CONCLUSIONS 
The findings of new epidemiology evaluations published since the most recent IARC 
review in 2009 add further weight to the view that consumption of alcoholic 
beverages is causally associated with risk of cancers of the oral cavity and pharynx, 
larynx, oesophagus (squamous cell carcinoma), female breast, colorectum, and liver. 
Alcohol consumption is also associated with cancer of the pancreas, although it is 
not clear whether this is a causal association.  
The new publications show: 
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 At low, medium and high alcohol intakes, a statistically significant 
increased risk at the following cancer sites:  
- oral cavity and pharynx (combined)  
- oesophagus (squamous cell carcinoma)  
- female breast 
 At medium and high alcohol intakes (i.e. generally at intakes >12.5 g 
ethanol/day, or > approximately 1.5 UK units/day), a statistically significant 
increased cancer risk at the following cancer sites:  
- larynx  
- colorectum 
 At high levels of alcohol intake (i.e. generally at intakes >50 g ethanol/day, 
or > approximately 6 UK units/day), a statistically significant increased cancer 
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COMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER 
PRODUCTS AND THE ENVIRONMENT. 
STATEMENT ON CONSUMPTION OF ALCOHOLIC BEVERAGES AND RISK OF 
CANCER. 
Definitions of evidence, as used in IARC Monographs for studies in humans 
(IARC, 2012) 
The evidence relevant to carcinogenicity from studies in humans is classified into 
one of the following categories. In some instances, these categories may be used to 
classify the degree of evidence related to carcinogenicity in specific organs or 
tissues. 
Sufficient evidence of carcinogenicity: The Working Group considers that a 
causal relationship has been established between exposure to the agent and human 
cancer. That is, a positive relationship has been observed between the exposure and 
cancer in studies in which chance, bias and confounding could be ruled out with 
reasonable confidence. A statement that there is sufficient evidence is followed by a 
separate sentence that identifies the target organ(s) or tissue(s) where an increased 
risk of cancer was observed in humans. Identification of a specific target organ or 
tissue does not preclude the possibility that the agent may cause cancer at other 
sites. 
Limited evidence of carcinogenicity: A positive association has been observed 
between exposure to the agent and cancer for which a causal interpretation is 
considered by the Working Group to be credible, but chance, bias or confounding 
could not be ruled out with reasonable confidence. 
Inadequate evidence of carcinogenicity: The available studies are of insufficient 
quality, consistency or statistical power to permit a conclusion regarding the 
presence or absence of a causal association between exposure and cancer, or no 
data on cancer in humans are available. 
Evidence suggesting lack of carcinogenicity: There are several adequate studies 
covering the full range of levels of exposure that humans are known to encounter, 
which are mutually consistent in not showing a positive association between 
exposure to the agent and any studied cancer at any observed level of exposure. 
The results from these studies alone or combined should have narrow confidence 
intervals with an upper limit close to the null value (e.g. a relative risk of 1.0). Bias 
and confounding should be ruled out with reasonable confidence, and the studies 
should have an adequate length of follow-up. A conclusion of evidence suggesting 
lack of carcinogenicity is inevitably limited to the cancer sites, conditions and levels 
of exposure, and length of observation covered by the available studies. In addition, 
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COMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER 
PRODUCTS AND THE ENVIRONMENT. 
STATEMENT ON CONSUMPTION OF ALCOHOLIC BEVERAGES AND RISK OF 
CANCER. 
Strategy and keywords/terms used in literature search. 
Literature searches were performed using Pubmed for all epidemiological studies 
relating to alcohol and site-specific cancers published between January 2008 and 
the time of presentation of each paper to the Committee. This time frame ensured 
that all studies published since the last IARC review, were identified. Reference lists 
from all relevant studies, reviews and meta-analyses published on the alcohol–
cancer association were also checked to identify additional studies. Non-English-
language publications were excluded. Publications that had been reviewed by IARC 
in 2009 were also excluded. 
Upper aerodigestive tract cancers (grouped) 
Papers were included from the searches for oral cavity and pharyngeal, oesophageal 
and laryngeal cancers where data for the cancers were combined. 
Oral cavity and pharyngeal cancers 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, oral cavity cancer, pharyngeal cancer, mouth cancer, lip 
cancer, tongue cancer, carcinoma, risk. Search Publication dates: January 2008 – 
December 2014. 
Oesophageal cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, oesophagus, oesophageal cancer, carcinoma, risk. Search 
Publication dates: January 2008 – December 2014. 
Laryngeal cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, larynx, laryngeal cancer, carcinoma, risk. Search 
Publication dates: January 2008 – December 2014. 
Breast cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, female, breast cancer, risk. Search Publication dates: 
January 2008 – September 2014. 
53 
Pancreatic cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, pancreas, pancreatic cancer, risk. Search Publication 
dates: January 2008 – January 2014. 
Liver cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, hepatocellular, liver cancer, risk. Search Publication dates: 
January 2008 – April 2014. 
Colorectal cancer 
Search terms were ethanol, alcohol, drinking, consumption, alcoholic beverages, 
beer, wine, spirits, liquor, colon, rectum, colorectal cancer, risk. Search Publication 
dates: January 2008 – September 2014. 
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Annex C 
COMMITTEE ON CARCINOGENICITY OF CHEMICALS IN FOOD, CONSUMER 
PRODUCTS AND THE ENVIRONMENT. 
STATEMENT ON CONSUMPTION OF ALCOHOLIC BEVERAGES AND RISK OF 
CANCER. 
The Newcastle-Ottawa scale for assessment of study quality. 
Assessment of the quality of the cohort studies and case-control studies reviewed for 
the Committee’s work on alcohol and cancer was carried out using a modified 
version of the Newcastle-Ottawa Scale (NOS) (resulting from collaboration between 
the Universities of Newcastle, Australia and Ottawa, Canada). Pooled and meta-
analyses were not scored.  
The NOS uses a 'star system' in which a study is judged on three broad 
perspectives: the selection of the study groups; the comparability of the groups; and 
the ascertainment of either the exposure or outcome of interest for case-control or 
cohort studies respectively (Wells et al, accessed 2015).  
The alcohol quality assessment considered three specific areas: 1) study design, 2) 
alcohol consumption data collection methods, and 3) data analysis. For many of the 
cancer sites reviewed, smoking was considered the most important confounder with 
other factors such as BMI, caffeine intake etc. also being important. For ease of 
reviewing the causal sites where a large number of papers had been identified 
(breast and oesophageal cancer studies), the cohort studies and case-control 
studies were further divided into two categories: a) those examining cancer 
incidence, and b) those examining cancer mortality. Within each section, the studies 
were reported by geographic region (UK, Europe, US, and other regions) and, within 
each region, in order of their modified Newcastle-Ottawa (NO) score, beginning with 
the highest scoring study.  
The template for the NOS scoring used for the COC review is given on the next 
page. 
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Cohort Studies: Alcohol and Cancer - Scoring System to assess study quality 







Study Design Star 
Rating 
1 Representatives of the 
exposed cohort 
a) Truly representative of the average  
_____________(describe) in the 
community 
b) Somewhat representative of the 
average in the community   
c) Selected group of users eg nurses, 
volunteers 
d) No description of the derivation of 
the cohort 
 
2 Selection of the non-
exposed cohort 
a) Drawn from the same community 
as the exposed cohort 
b) Drawn from a different source 
c) No description of the derivation of 
the non exposed cohort  
 
3 Ascertainment of 
exposure 
a) Secure record (eg surgical records)  
b) Structured interview 
c) Written self-report 
d) No description 
 
4 Demonstration that 
outcome of interest was 







1 Comparability of cohorts 
on the basis of the design 
or analysis 
a) Study controls for ____________ 
(select the most important factor)  
b) Study controls for any additional 
factor ________________  
(this criteria could be modified to 





1 Assessment of outcome a) Independent blind assessment 
b) Record linkage 
c) Self-report  
d) No description 
 
2 Was follow-up long 
enough for outcomes to 
occur 
a) Yes (select and adequate follow up 




Cohort Studies: Alcohol and Cancer - Scoring System to assess study quality 
3 Adequacy of follow up of 
cohorts 
a) Complete follow-up – all subjects 
accounted for 
b) Subjects lost to follow up unlikely to 
introduce bias – small number lost - 
___% (select an adequate %) 
follow up, or description provided of 
those lost 
c) Follow up rate __ % (select an 
adequate %) and no description of 
those lost 
d) No statement 
 
Total Star Score  
Susceptibility to biases 
1. Non-differential measurement error   
2. Dependent/differential measurement error  
3. Selection bias (baseline or follow-up   
4. Inadequate control of confounding   
5. Biased control selection  
6. Poor data on modifier  
7. Other (specify): _________  
Additional common topics 
1. Implausible temporal relationship  
2. Dose-response implausible  
3. Effects only in subgroups  
4. Errors in analysis or statistical inference  
5. Crude versus adjusted implausible   
6. Inadequate statistical power  
7. Multiple comparisons  
8. Lack of generalizability  
9. Other (specify): _________________  
Alcohol consumption data  Yes No 
Did the study contain any information on the following 
1. Dose –response analysis   
2. Frequency and duration of alcohol consumption   
3. Different drinking patterns (light, heavy, binge)   
4. Alcohol-free days   
Did the study consider beverage type individually (ie beer, wine, 
spirits)? 
  
In relation to Alcohol consumption, did the study stratify or 
consider the interaction with 
Yes No 
Smoking   
Obesity/BMI   
Caffeine   
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Case-Control Studies:  Alcohol and Cancer - Scoring System to assess study 
quality 







Study Design Star 
Rating 
1 Is the case definition 
adequate? 
a) Yes, with independent validation 
b) Yes, e.g. record linkage or 
based on self-reports 
c) No description 
 
2 Representativeness of the 
cases 
a) Consecutive or obviously 
representative series of cases 
b) Potential for selection biases or 
not stated 
c) No description 
 
3 Selection of controls a) Community controls 
b) Hospital controls 
c) No description 
 
4 Definition of controls a) No history of disease (endpoint)  




1 Comparability of cases and 
controls on the basis of the 
design or analysis 
a) Study controls for 
_____________ (select the 
most important factor)  
b) Study controls for any additional 
factor _________________  
(this criteria could be modified to 
indicate specific control for a 




1 Ascertainment of exposure a) Secure record 
b) Structured interview where blind 
to case/control status 
c) Interview not blinded to 
case/control status 
d) Written self-report or medical 
record only 
e) No description 
 
2 Same method of 





3 Non-response rate a) Same rate for both groups 
b) Non-respondents described 
c) Rate difference and no 
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Case-Control Studies:  Alcohol and Cancer - Scoring System to assess study 
quality 
designation 
Total Star Score  
Susceptibility to biases 
1. Non-differential measurement error   
2. Dependent/differential measurement 
error 
 
3. Selection bias (baseline or follow-up)  
4. Inadequate control of confounding   
5. Biased control selection   
6. Poor data on modifier  
7. Other (specify): _________  
Additional common topics 
1. Implausible temporal relationship   
2. Dose-response implausible  
3. Effects only in subgroups  
4. Errors in analysis or statistical inference  
5. Crude versus adjusted implausible   
6. Inadequate statistical power  
7. Multiple comparisons  
8. Lack of generalizability  
9. Other (specify): _________________  
Alcohol consumption data  Yes No 
Did the study contain any of the following information 
1. Dose –response analysis   
2. Frequency and duration of alcohol consumption   
3. Different drinking patterns (light, heavy, binge)   
4. Alcohol-free days   
Did the study consider beverage type individually (ie beer, 
wine, spirits)? 
  
In relation to Alcohol consumption, did the study stratify 
or consider the interaction with 
Yes No 
Smoking   
Obesity/BMI   
Caffeine   
 
